<html lang="en" class="pb-page js" data-request-id="94d62b01425af1d2-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d62b01425af1d2-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/dpJ3Ol7mIrfqEAx8i236u3Uuw7m4OrfEXhuTkmWHx2LTUWLsnCQS7dOi-4GeTD8FVLb5q-bkgKZMJ5QbklqeSw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d62b01425af1d2-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.4789499419508717"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Hematology/Oncology|Gastroenterology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Treatments in Oncology|Liver Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1915745","title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Liver Disease","specialties":"Hematology/Oncology|Gastroenterology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-05-14T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology|Gastroenterology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Liver Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1915745","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Atezolizumab + Bevacizumab for Hepatocellular Carcinoma","doi":"10.1056/NEJMdo005748","issueDate":"2020-05-14T00:00Z","age":"6Months-1990","isFree":"y","topics":"Treatments in Oncology|Liver Disease","viewType":"Full","specialties":"Hematology/Oncology|Gastroenterology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d62b01425af1d2-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma"><meta name="dc.Creator" content="Richard S. Finn"><meta name="dc.Creator" content="Shukui Qin"><meta name="dc.Creator" content="Masafumi Ikeda"><meta name="dc.Creator" content="Peter R. Galle"><meta name="dc.Creator" content="Michel Ducreux"><meta name="dc.Creator" content="Tae-You Kim"><meta name="dc.Creator" content="Masatoshi Kudo"><meta name="dc.Creator" content="Valeriy Breder"><meta name="dc.Creator" content="Philippe Merle"><meta name="dc.Creator" content="Ahmed O. Kaseb"><meta name="dc.Creator" content="Daneng Li"><meta name="dc.Creator" content="Wendy Verret"><meta name="dc.Creator" content="Derek-Zhen Xu"><meta name="dc.Creator" content="Sairy Hernandez"><meta name="dc.Creator" content="Juan Liu"><meta name="dc.Creator" content="Chen Huang"><meta name="dc.Creator" content="Sohail Mulla"><meta name="dc.Creator" content="Yulei Wang"><meta name="dc.Creator" content="Ho Yeong Lim"><meta name="dc.Creator" content="Andrew X. Zhu"><meta name="dc.Creator" content="Ann-Lii Cheng"><meta name="dc.Description" content="The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.In a global, open-..."><meta name="Description" content="The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.In a global, open-..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-05-14"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1915745"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202005143822009"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2004851"><meta name="dc.Relation" content="YXQYoa1915745"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1915745">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1915745">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1915745">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM">
        <meta property="og:title" content="Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1915745">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/3eb2d908-01f0-4fc5-9e75-c18c7ab8aa6d/nejmoa1915745_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/3eb2d908-01f0-4fc5-9e75-c18c7ab8aa6d/nejmoa1915745_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The combination of atezolizumab and bevacizumab showed encouraging antitumor activity
and safety in a phase 1b trial involving patients with unresectable hepatocellular
carcinoma. In a global, open...">
        <meta name="twitter:description" content="The combination of atezolizumab and bevacizumab showed encouraging antitumor activity
and safety in a phase 1b trial involving patients with unresectable hepatocellular
carcinoma. In a global, open...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2370">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1915745">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1915745">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2020.382.issue-20;article:article:doi\:10.1056/NEJMoa1915745;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1915745" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1915745" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1915745" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1915745" class="inputDoi"><input type="hidden" value="R.S. Finn and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:1894-1905" class="inputCitation"><input type="hidden" value="05-13-2020" class="inputEPubDate"><input type="hidden" value="May 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d62b01425af1d2-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Richard S.</span> <span property="familyName">Finn</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shukui</span> <span property="familyName">Qin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Masafumi</span> <span property="familyName">Ikeda</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter R.</span> <span property="familyName">Galle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michel</span> <span property="familyName">Ducreux</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tae-You</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Masatoshi</span> <span property="familyName">Kudo</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+14</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Valeriy</span> <span property="familyName">Breder</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philippe</span> <span property="familyName">Merle</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ahmed O.</span> <span property="familyName">Kaseb</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daneng</span> <span property="familyName">Li</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wendy</span> <span property="familyName">Verret</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Derek-Zhen</span> <span property="familyName">Xu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sairy</span> <span property="familyName">Hernandez</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Juan</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chen</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sohail</span> <span property="familyName">Mulla</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yulei</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ho Yeong</span> <span property="familyName">Lim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew X.</span> <span property="familyName">Zhu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Ann-Lii</span> <span property="familyName">Cheng</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the IMbrave150 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-14</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">May 13, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">1894</span>-<span property="pageEnd">1905</span></div><div class="doi">DOI: 10.1056/NEJMoa1915745</div><div class="core-enumeration"><a href="/toc/nejm/382/20"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">20</span></span></a></div><div><a href="#tab-information">Copyright Â© 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRichard%2BS.%2BFinn%252C%2BShukui%2BQin%252C%2BMasafumi%2BIkeda%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D20%26contentID%3D10.1056%252FNEJMoa1915745%26title%3DAtezolizumab%2Bplus%2BBevacizumab%2Bin%2BUnresectable%2BHepatocellular%2BCarcinoma%26publicationDate%3D05%252F14%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1915745" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRichard%2BS.%2BFinn%252C%2BShukui%2BQin%252C%2BMasafumi%2BIkeda%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D20%26contentID%3D10.1056%252FNEJMoa1915745%26title%3DAtezolizumab%2Bplus%2BBevacizumab%2Bin%2BUnresectable%2BHepatocellular%2BCarcinoma%26publicationDate%3D05%252F14%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/8d382e02-a63b-4daf-ab80-e5d2cc694a50/nejmoa1915745.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1915745.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1915745" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1915745.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">The intention-to-treat population included 336 patients in the atezolizumabâbevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumabâbevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P&lt;0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumabâbevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P&lt;0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumabâbevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumabâbevacizumab group; however, other high-grade toxic effects were infrequent.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. HoffmannâLa Roche/Genentech; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03434379" target="_blank">NCT03434379</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo005748/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005748" data-multimedia-filename="NEJMdo005748_600x400.jpg">
                <img src="/cms/asset/08881cae-fb7b-491e-8343-f8393524685c/media/NEJMdo005748_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005748" data-multimedia-filename="NEJMdo005748_600x400.jpg">Atezolizumab + Bevacizumab for Hepatocellular Carcinoma</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Hepatocellular carcinoma is a common cancer worldwide and a leading cause of cancer-related death.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Although early-stage disease may be curable by resection, liver transplantation, or ablation,<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-1" href-manipulated="true" aria-label="Reference 2">2</a></sup> most patients present with unresectable disease and have a poor prognosis.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup></div><div role="paragraph">The multikinase inhibitors sorafenib and lenvatinib are the approved first-line systemic treatments for unresectable hepatocellular carcinoma on the basis of studies showing modestly longer survival with sorafenib than with placebo<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> and noninferiority of lenvatinib to sorafenib.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-1" href-manipulated="true" aria-label="Reference 4">4</a></sup> Both are associated with considerable side effects that impair quality of life.</div><div role="paragraph">Programmed death 1 (PD-1) inhibitors have shown promising clinical activity as second-line treatment for hepatocellular carcinoma in phase 1/2 studies.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6" href-manipulated="true">5,6</a></sup> However, despite being associated with response rates in the range of 15 to 20% in phase 3 studies of single-agent treatment in first- and second-line settings, they did not significantly improve overall survival.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-1" href-manipulated="true">7,8</a></sup></div><div role="paragraph">Several active intrinsic immune-evasion pathways, including overexpression of vascular endothelial growth factor (VEGF), have been linked to the development and progression of liver cancer.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10" id="body-ref-r10" href-manipulated="true">9,10</a></sup> Anti-VEGF therapies reduce VEGF-mediated immunosuppression within the tumor and its microenvironment<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13" id="body-ref-r13" href-manipulated="true">11-13</a></sup> and may enhance antiâPD-1 and antiâprogrammed death ligand 1 (PD-L1) efficacy by reversing VEGF-mediated immunosuppression and promoting T-cell infiltration in tumors.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15" href-manipulated="true">14,15</a></sup></div><div role="paragraph">Several cancer immunotherapies that target the PD-L1âPD-1 pathway (i.e., checkpoint inhibitors) are currently being evaluated in patients with hepatocellular carcinoma.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-1" href-manipulated="true" aria-label="Reference 16">16</a></sup> Atezolizumab selectively targets PD-L1 to prevent interaction with receptors PD-1 and B7-1, thus reversing T-cell suppression.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> Bevacizumab is a monoclonal antibody that targets VEGF,<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> inhibits angiogenesis and tumor growth,<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> and showed response rates of 13 to 14% in single-agent phase 2 studies in patients with advanced liver cancer.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r20 r21 r22" id="body-ref-r22" href-manipulated="true">16,20â22</a></sup> A phase 1b study of atezolizumab plus bevacizumab in patients with untreated unresectable hepatocellular carcinoma showed an acceptable side-effect profile and promising antitumor activity, with an objective response rate of 36% and a median progression-free survival of 7 months.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-1" href-manipulated="true" aria-label="Reference 23">23</a></sup> We conducted IMbrave150, a global, multicenter, open-label, phase 3 randomized trial, to determine the safety and efficacy of atezolizumab plus bevacizumab as compared with sorafenib in patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Eligible patients were 18 years of age or older and had locally advanced metastatic or unresectable hepatocellular carcinoma (or both), with the diagnosis confirmed by histologic or cytologic analysis or clinical features according to the American Association for the Study of Liver Diseases criteria for patients with cirrhosis.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> Eligible patients had not previously received systemic therapy for liver cancer and had measurable disease, as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), that was not amenable to curative or locoregional therapies or that had progressed thereafter; a performance status score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale (scores range from 0 to 5, with higher numbers reflecting greater disability); an A classification on the ChildâPugh liver function scale (a three-category scale [A, B, or C], with C indicating the most severe compromise of liver function); and adequate hematologic and organ function.</div><div role="paragraph">Among the key exclusion criteria were a history of autoimmune disease, coinfection with hepatitis B or hepatitis C virus, and untreated or incompletely treated esophageal or gastric varices (assessed with esophagogastroduodenoscopy and treated according to local clinical practice) with bleeding or high risk of bleeding. Full eligibility criteria are provided in the trial <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Oversight</h3><div role="paragraph">F. HoffmannâLa Roche/Genentech sponsored the trial, provided the trial drugs, and collaborated with an academic steering committee on the trial design and on the collection, analysis, and interpretation of the data. IMbrave150 was conducted in accordance with the International Conference on Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. All patients gave written informed consent. Protocol approval was obtained from the institutional review board or ethics committee at each site. An independent data monitoring committee reviewed unmasked safety and trial conduct data approximately every 6 months. All drafts of the manuscript were prepared by the authors, with editorial assistance funded by the sponsor. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-3"><h3>Trial Design and Interventions</h3><div role="paragraph">In this open-label, phase 3 trial, patients were randomly assigned in a 2:1 ratio to receive atezolizumab plus bevacizumab or sorafenib. Randomization was performed through an interactive voice-response or Web-response system in permuted blocks, stratified by geographic region (Asia excluding Japan vs. the rest of the world), macrovascular invasion or extrahepatic spread of disease (presence vs. absence), baseline alpha-fetoprotein level (&lt;400 vs. â¥400 ng per milliliter), and ECOG performance status (0 vs. 1).</div><div role="paragraph">Patients assigned to the atezolizumabâbevacizumab group received 1200 mg of atezolizumab plus 15 mg per kilogram of body weight of bevacizumab intravenously every 3 weeks; patients assigned to the sorafenib group received 400 mg of sorafenib orally twice daily. Patients received their assigned drugs until unacceptable toxic effects occurred or there was loss of clinical benefit. Patients could continue treatment beyond disease progression if the investigator observed evidence of clinical benefit and if symptoms and signs indicating unequivocal disease progression were absent. Dose modifications were not permitted in the atezolizumabâbevacizumab group but were allowed in the sorafenib group. Patients who transiently or permanently discontinued either atezolizumab or bevacizumab because of an adverse event were allowed to continue taking single-agent therapy as long as the investigator determined that there was clinical benefit.</div></section><section id="sec-1-4"><h3>Assessments</h3><div role="paragraph">Tumors were assessed by computed tomography or magnetic resonance imaging at baseline and every 6 weeks until week 54 and then every 9 weeks thereafter. (Assessments and patient-reported outcomes are described in detail in the Supplementary Methods section in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.)</div><div role="paragraph">Safety was continuously evaluated by vital signs and clinical laboratory test results and assessment of the incidence and severity of adverse events according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version 4.0. Patient-reported outcomes were evaluated with the use of the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire for cancer (EORTC QLQâC30).</div></section><section id="sec-1-5"><h3>End Points</h3><div role="paragraph">The coprimary end points were overall survival (the time from randomization to death from any cause) and progression-free survival (the time from randomization to disease progression according to RECIST 1.1, as assessed at an independent review facility, or death from any cause, whichever occurred first). Secondary end points included the objective response rate (the percentage of patients with a confirmed complete or partial response) and the duration of response (the time from first documented complete or partial response to disease progression or death) according to investigator-assessed and independently-assessed RECIST 1.1 and hepatocellular carcinomaâspecific modified RECIST (mRECIST)<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> criteria; and the time to deterioration of quality of life, physical functioning, and role functioning, as reported by the patient, with deterioration defined as a decrease from baseline of 10 points or more on the EORTC QLQâC30 maintained for two consecutive assessments or a decrease of 10 points or more in one assessment followed by death from any cause within 3 weeks. Safety and side-effect profiles were assessed on the basis of the nature, frequency, and severity of adverse events, according to NCI Common Terminology Criteria for Adverse Events, version 4.0. The full list of end points is described in the <a href="#ap1">protocol</a>.</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">We estimated that a sample size of 480 patients, targeting 312 deaths, would provide 80% power to detect a hazard ratio for overall survival of 0.71 favoring atezolizumabâbevacizumab over sorafenib using a log-rank test at a two-sided 0.048 significance level. The two-sided significance level for progression-free survival was 0.002. The overall type I error (0.05) was controlled through the use of a graphical approach<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27" href-manipulated="true">26,27</a></sup> (see the protocol and the Supplementary Methods and Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). Independently-assessed objective response rates, according to RECIST 1.1 and hepatocellular carcinomaâspecific mRECIST, were also part of the statistical testing hierarchy.</div><div role="paragraph">One analysis of progression-free survival, two interim analyses, and a final analysis of overall survival were planned. The primary analysis was to be conducted after approximately 308 occurrences of disease progression or death, and the first interim analysis of overall survival was planned to occur at the same time. By August 29, 2019, a total of 306 instances of disease progression or death, including 161 deaths, had occurred. On the basis of the observed number of deaths, the multiplicity-adjusted, two-sided alpha level for the first interim analysis of overall survival was 0.0033.</div><div role="paragraph">Efficacy was assessed in all patients who had been randomly assigned to treatment (the intention-to-treat population). Both overall and progression-free survival were compared between treatment groups with the use of a stratified log-rank test, and hazard ratios for disease progression or death were estimated with a stratified Cox proportional-hazards model. KaplanâMeier analysis was applied to overall and progression-free survival, duration of response (in patients who had confirmed response), and time to deterioration for patient-reported outcomes. Confirmed response rates were compared between treatment groups with the stratified CochranâMantelâHaenszel test. The randomization stratification factors were applied to all stratified efficacy analyses except ECOG performance status. Patients included in safety evaluations were those who had received at least one dose of trial treatment.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients and Treatment</h3><div role="paragraph">Between March 15, 2018, and January 30, 2019, a total of 501 patients at 111 sites in 17 countries (Table S1) were randomly assigned to receive atezolizumab plus bevacizumab (336 patients) or sorafenib (165 patients) and were included in the intention-to-treat population (Fig. S2). Baseline characteristics were generally well balanced between treatment groups (<a href="#t1">Table 1</a>, and Table S2). Follow-up therapies are summarized in Table S3.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t1.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/4ce30c5d-9695-4edb-8010-151ce4a7f2c2/assets/images/large/nejmoa1915745_t1.jpg" height="2375" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">AtezolizumabâBevacizumab<br>(N=336)</th><th class="txxr-borders">Sorafenib<br>(N=165)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) â yr</td><td class="xxxx-borders shading">64 (56â71)</td><td class="xxxr-borders shading">66 (59â71)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">277 (82)</td><td class="xxxr-borders">137 (83)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Geographic region â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asia, excluding Japan</td><td class="xxxx-borders">133 (40)</td><td class="xxxr-borders">68 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Rest of the world<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">203 (60)</td><td class="xxxr-borders shading">97 (59)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ECOG performance status score â no. (%)<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">209 (62)</td><td class="xxxr-borders shading">103 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">127 (38)</td><td class="xxxr-borders">62 (38)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ChildâPugh classification â no./total no. (%)<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">A5</td><td class="xxxx-borders">239/333 (72)</td><td class="xxxr-borders">121/165 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">A6</td><td class="xxxx-borders shading">94/333 (28)</td><td class="xxxr-borders shading">44/165 (27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Barcelona Clinic liver cancer stage â no. (%)<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">A</td><td class="xxxx-borders shading">8 (2)</td><td class="xxxr-borders shading">6 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">B</td><td class="xxxx-borders">52 (15)</td><td class="xxxr-borders">26 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">276 (82)</td><td class="xxxr-borders shading">133 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Alpha-fetoprotein â¥400 ng per milliliter â no. (%)</td><td class="xxxx-borders">126 (38)</td><td class="xxxr-borders">61 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Presence of macrovascular invasion, extrahepatic spread, or both â no. (%)</td><td class="xxxx-borders shading">258 (77)</td><td class="xxxr-borders shading">120 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Macrovascular invasion</td><td class="xxxx-borders">129 (38)</td><td class="xxxr-borders">71 (43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Extrahepatic spread</td><td class="xxxx-borders shading">212 (63)</td><td class="xxxr-borders shading">93 (56)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Varices â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Present at baseline</td><td class="xxxx-borders shading">88 (26)</td><td class="xxxr-borders shading">43 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Treated at baseline</td><td class="xxxx-borders">36 (11)</td><td class="xxxr-borders">23 (14)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Cause of hepatocellular carcinoma â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hepatitis B</td><td class="xxxx-borders">164 (49)</td><td class="xxxr-borders">76 (46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hepatitis C</td><td class="xxxx-borders shading">72 (21)</td><td class="xxxr-borders shading">36 (22)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonviral<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">100 (30)</td><td class="xxxr-borders">53 (32)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Prior local therapy for hepatocellular carcinoma â no. (%)</td><td class="xbxx-borders shading">161 (48)</td><td class="xbxr-borders shading">85 (52)</td></tr></tbody></table></div><figcaption><div class="caption">Patient Characteristics at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Percentages may not total 100 because of rounding. IQR denotes interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">The rest of the world includes the United States, Australia, New Zealand, and Japan.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5, with higher numbers reflecting greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">The ChildâPugh liver function scale is a three-category scale (A, with scores of 5 or 6, indicating good hepatic function; B, with scores of 7 to 9, indicating moderately impaired hepatic function; or C, with scores of 10 to 15, indicating advanced hepatic dysfunction). Classification is determined by scoring according to the presence and severity of five clinical measures of liver disease (encephalopathy, ascites, bilirubin levels, albumin levels, and prolonged prothrombin time). Data shown reflect patients in Class A with scores of 5 or 6 and thus good hepatic function. Precise numeric scores for two patients in the atezolizumabâbevacizumab group who were in Class A on the ChildâPugh scale were not available. Data are not included for one patient in the atezolizumabâbevacizumab group whose classification was B7.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">The Barcelona Clinic liver cancer staging system ranks hepatocellular carcinoma in 5 stages, beginning at 0 (very early stage) and progressing from A (early stage) to D (terminal stage).</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t1fn6" role="paragraph">Nonviral causes include alcohol, other, and unknown non-hepatitis B and C causes.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">As of the date of clinical data cutoff (August 29, 2019), the median duration of follow-up was 8.6 months (8.9 months in the atezolizumabâbevacizumab group and 8.1 months in the sorafenib group). A total of 96 patients (28.6%) in the atezolizumabâbevacizumab group and 65 (39.4%) in the sorafenib group died (stratified hazard ratio for death, 0.58; 95% confidence interval [CI], 0.42 to 0.79; P&lt;0.001) (<a href="#f1">Figure 1A</a>). <a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Overall survival was significantly longer with atezolizumabâbevacizumab; the estimated rates of survival at 6 months and 12 months were 84.8% (95% CI, 80.9 to 88.7) and 67.2% (95% CI, 61.3 to 73.1), respectively, in the atezolizumabâbevacizumab group and 72.2% (95% CI, 65.1 to 79.4) and 54.6% (95% CI, 45.2 to 64.0) in the sorafenib group.</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f1.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/3eb2d908-01f0-4fc5-9e75-c18c7ab8aa6d/assets/images/large/nejmoa1915745_f1.jpg" height="2370" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">KaplanâMeier Analysis of Overall and Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival (Panel A) and progression-free survival (Panel B), as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1, for patients in the intention-to-treat population. Stratified hazard ratios for progression or death are reported, along with P values. The two-sided P-value boundary calculated on the basis of 161 deaths is 0.0033. Randomization was performed through an interactive voice-response or Web-response system, and factors included in the stratified P value and Cox model were geographic region (Asia [excluding Japan] vs. the rest of the world), alpha-fetoprotein level at baseline (&lt;400 ng per milliliter vs. â¥400 ng per milliliter), and macrovascular invasion, extrahepatic spread, or both (yes vs. no). Tick marks indicate censored data. CI denotes confidence interval, and NE could not be evaluated.</div></div></figcaption></figure></div><div role="paragraph"><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">A total of 197 patients (58.6%) receiving atezolizumabâbevacizumab and 109 patients (66.1%) receiving sorafenib had disease progression or died. Progression-free survival was significantly longer with atezolizumabâbevacizumab than with sorafenib (median, 6.8 months [95% CI, 5.7 to 8.3] vs. 4.3 months [95% CI, 4.0 to 5.6]; stratified hazard ratio for progression or death, 0.59; 95% CI, 0.47 to 0.76; P&lt;0.001) (<a href="#f1">Figure 1B</a>)</span>. Progression-free survival at 6 months was 54.5% in the atezolizumabâbevacizumab group and 37.2% in the sorafenib group.</div><div role="paragraph">Given that results for progression-free survival were statistically significant, objective response rates were sequentially tested (<a href="#t2">Table 2</a>). The confirmed objective response rates were 27.3% (95% CI, 22.5 to 32.5) with atezolizumabâbevacizumab and 11.9% (95% CI, 7.4 to 18.0) with sorafenib, according to independent assessment with RECIST 1.1 (P&lt;0.001), and 33.2% (95% CI, 28.1 to 38.6) and 13.3% (95% CI, 8.4 to 19.6), respectively, according to hepatocellular carcinomaâspecific mRECIST (P&lt;0.001). Eighteen patients (5.5%) in the atezolizumabâbevacizumab group, as compared with no patients in the sorafenib treatment group, had a complete response. The disease control rate (objective response plus stable disease) was 73.6% with atezolizumabâbevacizumab and 55.3% with sorafenib (<a href="#t2">Table 2</a>). Investigator-assessed progression-free survival and objective response rates are summarized in Table S4.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t2.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/43d53d04-117f-49fc-9fc1-d850d7664c36/assets/images/large/nejmoa1915745_t2.jpg" height="1262" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>RECIST 1.1</span></th><th class="txxr-borders" colspan="3"><span>HCC-Specific mRECIST</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">AtezolizumabâBevacizumab<br>(N=326)</th><th class="xxxx-borders">Sorafenib<br>(N=159)</th><th class="xxxx-borders">Difference<br>(P Value)<a href="#t2fn2" role="doc-noteref">â </a></th><th class="xxxx-borders">AtezolizumabâBevacizumab<br>(N=325)</th><th class="xxxx-borders">Sorafenib<br>(N=158)</th><th class="xxxr-borders">Difference<br>(P Value)<a href="#t2fn2" role="doc-noteref">â </a></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confirmed objective response â no. (% [95% CI])<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">89<br>(27.3 [22.5â32.5])</td><td class="xxxx-borders shading">19<br>(11.9 [7.4â18.0])</td><td class="xxxx-borders shading">15.4<br> (&lt;0.001)</td><td class="xxxx-borders shading">108<br>(33.2 [28.1â38.6])</td><td class="xxxx-borders shading">21<br>(13.3 [8.4â19.6])</td><td class="xxxr-borders shading">19.9<br>(&lt;0.001)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response â no. (%)</td><td class="xxxx-borders">18 (5.5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">33 (10.2)</td><td class="xxxx-borders">3 (1.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response â no. (%)</td><td class="xxxx-borders shading">71 (21.8)</td><td class="xxxx-borders shading">19 (11.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">75 (23.1)</td><td class="xxxx-borders shading">18 (11.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Stable disease â no. (%)</td><td class="xxxx-borders">151 (46.3)</td><td class="xxxx-borders">69 (43.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">127 (39.1)</td><td class="xxxx-borders">66 (41.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Disease control rate â no. (%)<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">240 (73.6)</td><td class="xxxx-borders shading">88 (55.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">235 (72.3)</td><td class="xxxx-borders shading">87 (55.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Progressive disease â no. (%)</td><td class="xxxx-borders">64 (19.6)</td><td class="xxxx-borders">39 (24.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">66 (20.3)</td><td class="xxxx-borders">40 (25.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Could not be evaluated â no. (%)</td><td class="xxxx-borders shading">8 (2.5)</td><td class="xxxx-borders shading">14 (8.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">10 (3.1)</td><td class="xxxx-borders shading">14 (8.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Data missing â no. (%)</td><td class="xxxx-borders">14 (4.3)</td><td class="xxxx-borders">18 (11.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">14 (4.3)</td><td class="xxxx-borders">17 (10.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Ongoing objective response at data cutoff â no./total no. (%)</td><td class="xbxx-borders shading">77/89 (86.5)</td><td class="xbxx-borders shading">13/19 (68.4)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">84/108 (77.8)</td><td class="xbxx-borders shading">13/21 (61.9)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Secondary Efficacy Outcomes.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Included are patients who presented with measurable disease according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), and according to hepatocellular carcinoma (HCC)âspecific modified RECIST (mRECIST), as assessed at an independent review facility. CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">The difference is the between-group difference (atezolizumabâbevacizumab minus sorafenib) in the percentage of patients with confirmed response, expressed in percentage points. The P value was derived from a CochranâMantelâHaenszel test. Randomization, which was performed through an interactive voice-response or Web-response system, included as stratification factors geographic region (Asia excluding Japan vs. the rest of the world), alpha-fetoprotein level (&lt;400 ng per milliliter vs. â¥400 ng per milliliter) at baseline, and macrovascular invasion, extrahepatic spread, or both (yes vs. no).</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">Confirmed objective response was defined as a response (complete or partial) seen at two consecutive tumor assessments at least 28 days apart.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t2fn4" role="paragraph">The control rate is the sum of complete response, partial response, and stable disease.</div></div></div></figcaption></figure></div><div role="paragraph">The estimated percentage of patients with duration of response longer than 6 months was 87.6% in the atezolizumabâbevacizumab group and 59.1% in the sorafenib group. We observed similar durations of response using hepatocellular carcinomaâspecific mRECIST (<a href="#t2">Table 2</a>). The overall survival benefit and progression-free survival benefit with atezolizumabâbevacizumab as compared with sorafenib were generally consistent across the clinically relevant subgroups analyzed (Fig. S3).</div><div role="paragraph">For patient-reported outcomes, compliance with the EORTC QLQ-C30 questionnaire (defined as completion of at least one question) in the intention-to-treat population was at least 93% from baseline until treatment cycle 17 (56 patients at week 51), and was at least 80% thereafter until treatment was discontinued. Treatment with atezolizumabâbevacizumab delayed deterioration of patient-reported quality of life (median time to deterioration, 11.2 months with atezolizumabâbevacizumab vs. 3.6 months with sorafenib; hazard ratio, 0.63; 95% CI, 0.46 to 0.85) (<a href="#f2">Figure 2</a>), physical functioning (median time to deterioration, 13.1 months vs. 4.9 months; hazard ratio, 0.53; 95% CI, 0.39 to 0.73), and role functioning (median time to deterioration, 9.1 months vs. 3.6 months; hazard ratio, 0.62; 95% CI, 0.46 to 0.84) (Fig. S4).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f2.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/b59fbc43-f19b-4c1c-973c-cd57aa78c40e/assets/images/large/nejmoa1915745_f2.jpg" height="1331" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">KaplanâMeier Analysis of Time to Deterioration of Quality of Life.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of the time to deterioration in quality of life in the intention-to-treat population. Tick marks indicate censored data.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">A total of 485 patients received at least one dose of trial treatment (329 received atezolizumabâbevacizumab and 156 received sorafenib) and were included in safety analyses. The median duration of treatment was 7.4 months with atezolizumab, 6.9 months with bevacizumab, and 2.8 months with sorafenib. The mean (Â±SD) dose intensity was 95Â±7% for atezolizumab, 93Â±10% for bevacizumab, and 84Â±20% for sorafenib; the respective median dose intensities were 98% (range, 54 to 104), 97% (range, 44 to 104), and 96% (range, 27 to 100).</div><div role="paragraph">Adverse events of any grade regardless of causality were reported by 323 patients (98.2%) who received atezolizumabâbevacizumab and by 154 patients (98.7%) who received sorafenib (<a href="#t3">Table 3</a> and <a href="#t4">Table 4</a>, and Table S5). Grade 5 events occurred in 15 patients (4.6%) in the atezolizumabâbevacizumab group and in 9 patients (5.8%) in the sorafenib group. Serious adverse events occurred more frequently with atezolizumabâbevacizumab (125 patients [38.0%]) than with sorafenib (48 patients [30.8%]). No specific events were responsible for the increased incidence of serious adverse events in the atezolizumabâbevacizumab group. No serious adverse events with a difference between the treatment groups of 2% or more were noted. <a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">The most common grade 3 or 4 event with atezolizumabâbevacizumab was hypertension (15.2%), a finding consistent with the known safety profile of bevacizumab.</span> Treatment-related events that occurred in at least 10% of patients (or grade 3 or 4 events that occurred in â¥2%) are listed in Table S6. The percentage of patients who discontinued any treatment component because of adverse events was 15.5% in the atezolizumabâbevacizumab group (7% discontinued both components) and 10.3% in the sorafenib group (<a href="#t3">Table 3</a>). Adverse events leading to dose modification or interruption occurred in 49.5% of patients who were receiving atezolizumabâbevacizumab and in 60.9% who were receiving sorafenib (<a href="#t3">Table 3</a>). (Adverse events leading to treatment discontinuation and all-cause adverse events of special interest in patients receiving atezolizumab or bevacizumab are listed in Table S7 and Table S8, respectively.)</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t3.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/5bb5bd8d-0d1f-449c-8c5d-252bf5ba113e/assets/images/large/nejmoa1915745_t3.jpg" height="1152" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">AtezolizumabâBevacizumab<br>(N=329)</th><th class="txxr-borders">Sorafenib<br>(N=156)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients with an adverse event from any cause</td><td class="xxxx-borders shading">323 (98.2)</td><td class="xxxr-borders shading">154 (98.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Grade 3 or 4 event<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">186 (56.5)</td><td class="xxxr-borders">86 (55.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Grade 5 event<a href="#t3fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">15 (4.6)</td><td class="xxxr-borders shading">9 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders">125 (38.0)</td><td class="xxxr-borders">48 (30.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to withdrawal from any trial drug</td><td class="xxxx-borders shading">51 (15.5)</td><td class="xxxr-borders shading">16 (10.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Withdrawal from atezolizumabâbevacizumab</td><td class="xxxx-borders">23 (7.0)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to dose modification or interruption of any trial drug</td><td class="xxxx-borders shading">163 (49.5)</td><td class="xxxr-borders shading">95 (60.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dose interruption of any trial treatment</td><td class="xxxx-borders">163 (49.5)</td><td class="xxxr-borders">64 (41.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Dose modification of sorafenib</td><td class="xbxx-borders shading">â</td><td class="xbxr-borders shading">58 (37.2)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events from Any Cause.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Numbers represent the highest grades assigned.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t3fn2" role="paragraph">Grade 5 events in the atezolizumabâbevacizumab group included gastrointestinal hemorrhage (in 3 patients), pneumonia (in 2 patients), empyema, gastric ulcer perforation, abnormal hepatic function, liver injury, multiple-organ dysfunction syndrome, esophageal varices hemorrhage, subarachnoid hemorrhage, respiratory distress, sepsis, and cardiac arrest (in 1 patient each); grade 5 events in the sorafenib group included death (in 2 patients), hepatic cirrhosis (in 2 patients), cardiac arrest, cardiac failure, general physical health deterioration, hepatitis E, and peritoneal hemorrhage (in 1 patient each).</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 4</div><nav><a href="#t4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t4" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t4.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/601a5728-455c-47b6-af09-a831c78632c7/assets/images/large/nejmoa1915745_t4.jpg" height="1688" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>AtezolizumabâBevacizumab<br>(N=329)</span></th><th class="txxr-borders" colspan="2"><span>Sorafenib<br>(N=156)</span></th></tr><tr class="head2" data-type="row head2" data-xml-valign="top"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">98 (29.8)</td><td class="xxxx-borders shading">50 (15.2)</td><td class="xxxx-borders shading">38 (24.4)</td><td class="xxxr-borders shading">19 (12.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">67 (20.4)</td><td class="xxxx-borders">8 (2.4)</td><td class="xxxx-borders">29 (18.6)</td><td class="xxxr-borders">5 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Proteinuria</td><td class="xxxx-borders shading">66 (20.1)</td><td class="xxxx-borders shading">10 (3.0)</td><td class="xxxx-borders shading">11 (7.1)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Aspartate aminotransferase increase</td><td class="xxxx-borders">64 (19.5)</td><td class="xxxx-borders">23 (7.0)</td><td class="xxxx-borders">26 (16.7)</td><td class="xxxr-borders">8 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">64 (19.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (9.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">62 (18.8)</td><td class="xxxx-borders">6 (1.8)</td><td class="xxxx-borders">77 (49.4)</td><td class="xxxr-borders">8 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">58 (17.6)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">38 (24.4)</td><td class="xxxr-borders shading">6 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">59 (17.9)</td><td class="xxxx-borders">4 (1.2)</td><td class="xxxx-borders">15 (9.6)</td><td class="xxxr-borders">2 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Alanine aminotransferase increase</td><td class="xxxx-borders shading">46 (14.0)</td><td class="xxxx-borders shading">12 (3.6)</td><td class="xxxx-borders shading">14 (9.0)</td><td class="xxxr-borders shading">2 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">44 (13.4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">22 (14.1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Blood bilirubin increase</td><td class="xxxx-borders shading">43 (13.1)</td><td class="xxxx-borders shading">8 (2.4)</td><td class="xxxx-borders shading">22 (14.1)</td><td class="xxxr-borders shading">10 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rash</td><td class="xxxx-borders">41 (12.5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">27 (17.3)</td><td class="xxxr-borders">4 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders shading">40 (12.2)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">27 (17.3)</td><td class="xxxr-borders shading">4 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">40 (12.2)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">25 (16.0)</td><td class="xxxr-borders">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cough</td><td class="xxxx-borders shading">39 (11.9)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (9.6)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Infusion-related reaction</td><td class="xxxx-borders">37 (11.2)</td><td class="xxxx-borders">8 (2.4)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Weight decrease</td><td class="xxxx-borders shading">37 (11.2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (9.6)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Platelet count decrease</td><td class="xxxx-borders">35 (10.6)</td><td class="xxxx-borders">11 (3.3)</td><td class="xxxx-borders">18 (11.5)</td><td class="xxxr-borders">2 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Epistaxis</td><td class="xxxx-borders shading">34 (10.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (4.5)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Asthenia</td><td class="xxxx-borders">22 (6.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">21 (13.5)</td><td class="xxxr-borders">4 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Alopecia</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">22 (14.1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Palmarâplantar erythrodysesthesia syndrome</td><td class="xbxx-borders">3 (0.9)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">75 (48.1)</td><td class="xbxr-borders">13 (8.3)</td></tr></tbody></table></div><figcaption>Adverse Events with an Incidence of More Than 10% in Either Group.</figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The IMbrave150 trial showed significantly better overall survival and progression-free survival outcomes with atezolizumab plus bevacizumab than with sorafenib in patients with unresectable hepatocellular carcinoma who had received no previous systemic treatment. This benefit was generally consistent across clinical subgroups and confirms previous phase 1b findings that showed the clinical benefit of targeting both angiogenesis and PD-L1 signaling in unresectable liver cancer.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-2" href-manipulated="true" aria-label="Reference 23">23</a></sup> The early separation of the KaplanâMeier curves for overall survival was maintained over time despite a higher proportion of patients in the sorafenib group receiving subsequent systemic therapy, including immunotherapy. In addition, the trial population included a subgroup of particularly high-risk patients. Approximately 40% of patients had macrovascular invasion. The trial also included patients who had macrovascular invasion of the main portal trunk or the portal vein branch contralateral to the primarily involved lobe, bile duct invasion, or at least 50% hepatic involvement (or any combination of these three features) â patients who were excluded from other contemporary phase 3 trials of treatment for hepatocellular carcinoma.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r7" id="body-ref-r7-2" href-manipulated="true">4,7</a></sup></div><div role="paragraph">The 42% lower hazard of death and the significantly longer overall survival with atezolizumabâbevacizumab than with sorafenib in the IMbrave150 trial is underpinned by a 2.5-month increase in median progression-free survival, a corresponding 41% decrease in the hazard of disease progression or death, and a response rate of 27.3%, as well as the fact that 88% of patients who had a response (complete or partial) continued to have a response at 6 months. Furthermore, in the atezolizumabâbevacizumab group, the median time to deterioration in quality of life and functioning was markedly longer than the median progression-free survival, but this difference was not observed in the sorafenib group. The median duration of sorafenib treatment (2.8 months) was consistent with the median progression-free survival as assessed by the investigators (Table S4), because treatment decisions were made by the investigators according to their assessments of tumor responses.</div><div role="paragraph">The spectrum, incidence, and severity of adverse events observed with the combination of atezolizumab and bevacizumab were consistent with the known safety profile of each agent and the underlying disease. Approximately 15% of patients in the atezolizumabâbevacizumab group discontinued treatment owing to adverse events, as compared with 10% of patients in the sorafenib group. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">Gastrointestinal disorders were the most common reason for discontinuation in the atezolizumabâbevacizumab group, as expected in patients with liver cancer and underlying cirrhosis. Bleeding (including fatal events) is a known adverse reaction to bevacizumab, and upper gastrointestinal bleeding is a common and life-threatening complication in patients with cirrhosis and hepatocellular carcinoma. In this trial, patients had to be evaluated for the presence of varices before enrollment, and varices of any size were assessed and treated as needed according to local standards of care. Overall, the incidence of upper gastrointestinal bleeding observed in the atezolizumabâbevacizumab group was 7% (as compared with 4.5% in the sorafenib group), which is consistent with historical data in other trials of bevacizumab for hepatocellular carcinoma.</span><sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21" id="body-ref-r21-2" href-manipulated="true">20,21</a></sup></div><div role="paragraph">Previous studies of single-agent checkpoint inhibitors failed to show a survival benefit in patients with hepatocellular carcinoma.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-2" href-manipulated="true">7,8</a></sup> The randomized portion of the phase 1b study GO30140 showed significantly better progression-free survival outcomes with atezolizumab plus bevacizumab than with monotherapy with atezolizumab,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-3" href-manipulated="true" aria-label="Reference 23">23</a></sup> which suggests that both atezolizumab and bevacizumab contribute to the overall treatment benefit of the combination in patients with hepatocellular carcinoma.</div><div role="paragraph">In patients with previously untreated metastatic renal cell carcinoma, PD-L1 positivity has been shown to be associated with longer progression-free survival in patients who receive the combination of atezolizumab and bevacizumab than in patients who receive sunitinib.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> However, the predictive value of PD-L1 status for the efficacy of PD-L1 and PD-1 inhibitors or combination therapies has not been clearly shown in the case of hepatocellular carcinoma.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r8 r23" id="body-ref-r23-4" href-manipulated="true">5,8,23</a></sup> Further tissue or blood-based biomarker analyses (or both) will need to be conducted to identify biomarkers of response and to determine the patients who would benefit most from atezolizumabâbevacizumab therapy.</div><div role="paragraph">The trial has several limitations. The open-label design was used to spare patients from two placebo infusions. To minimize the potential bias associated with the open-label design, a blinded independent review of imaging for progression-free survival was selected for the coprimary end point. The trial was conducted in a patient population that had preserved liver function (ChildâPugh class A) and a decreased risk of variceal bleeding. The safety of the combination in a broader population warrants further study.</div><div role="paragraph">In conclusion, treatment with atezolizumab plus bevacizumab was associated with significantly better overall survival and progression-free survival outcomes than sorafenib in patients with advanced unresectable hepatocellular carcinoma not previously treated with systemic therapy. Serious toxic effects were noted in 38% of the patients who received the combination therapy; however, no new or unexpected toxic effects were observed. The combination therapy also resulted in a longer time to deterioration of patient-reported quality of life and functioning than sorafenib.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was updated on May 19, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">F. HoffmannâLa Roche/Genentech</span>.</div><div role="paragraph">Dr. Finn reports receiving fees for serving on a data and safety monitoring board from AstraZeneca and consulting fees from Bayer, Bristol Myers Squibb, CStone, Eisai, Eli Lilly, Exelixis, F. HoffmannâLa Roche, Genentech USA, Merck, Novartis Pharma, and Pfizer; Dr. Ikeda, receiving grant support (paid to National Cancer Center Hospital East) from AstraZeneca, Baxalta, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, J-Pharma, Ono Pharmaceutical, and Yakult Honsha, grant support (paid to National Cancer Center Hospital East) and lecture fees from Bayer, Eisai, Merck Sharp &amp; Dohme, and Novartis, and lecture fees from EA Pharma, Gilead Sciences, Taiho Pharmaceutical, and Teijin Pharma; Dr. Galle, receiving consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, F. HoffmannâLa Roche, Ipsen Biopharmaceuticals, Merck Sharp &amp; Dohme, and Sirtex Medical; Dr. Ducreux, receiving advisory board fees, lecture fees, and travel support from Amgen and F. HoffmannâLa Roche, lecture fees, consulting fees, and travel support from Bayer, lecture fees from Eli Lilly, advisory board fees and lecture fees from Ipsen Biopharm Limited, lecture fees and travel support from Merck, and advisory board fees and travel support from Servier; Dr. Kudo, receiving grant support from AbbVie, Dainippon Sumitomo Pharma, Gilead Sciences, Otsuka Pharmaceutical, Taiho Pharmaceutical, and Takeda Medical Research Foundation, grant support and consulting fees from Bayer and Merck, grant support, lecture fees, and consulting fees from Bristol Myers Squibb and Eisai, and consulting fees from Chugai Pharmaceutical and Ono Pharmaceutical; Dr. Breder, receiving travel support from Bayer Healthcare, advisory board fees and lecture fees from Bristol Myers Squibb, Eisai, and Merck, and advisory board fees, lecture fees, and travel support from F. HoffmannâLa Roche; Dr. Merle, receiving advisory board fees from Bayer Healthcare, Bristol Myers Squibb, Eisai, Eli Lilly, Ipsen Biopharmaceuticals, Merck, and Roche; Dr. Kaseb, receiving grant support and advisory board fees from Genentech USA; Dr. Li, receiving fees for serving on a speakers bureau from Advanced Accelerator Applications, advisory board fees from Bayer Healthcare, Genentech USA, and Taiho Pharmaceutical, fees for serving on a speakers bureau and advisory board fees from Eisai, Exelixis, Ipsen Biopharmaceuticals, and Lexicon Pharmaceuticals, and lecture fees from Novartis; Dr. Verret, being employed by Genentech USA; Dr. Xu, being employed by F. HoffmannâLa Roche; Dr. Hernandez, being employed by Genentech USA; Dr. Liu, being employed by F. HoffmannâLa Roche; Dr. Huang, being employed by F. HoffmannâLa Roche; Dr. Mulla, being employed by and owning stock in HoffmannâLa Roche; Dr. Wang, being employed by and owning stock in Genentech USA; Dr. Lim, receiving fees for serving as an expert witness from Bayer Healthcare, Eisai, Eli Lilly, F. HoffmannâLa Roche, and Ipsen Biopharmaceuticals; Dr. Zhu, receiving consulting fees from Bayer, Eisai, Eli Lilly, Exelixis, F. HoffmannâLa Roche, Merck, and Sanofi Aventis; and Dr. Cheng, receiving fees for serving on a speakers bureau from Amgen Taiwan and Eisai Taiwan, consulting fees from AstraZeneca, Bayer Healthcare Pharmaceuticals, BeiGene, Bristol Myers Squibb, CSR Pharma Group, Eisai, Exelixis, F. HoffmannâLa Roche, Ipsen Innovation, Merck Sharp &amp; Dohme, and Ono Pharmaceutical, consulting fees and fees for serving on a speakers bureau from Bayer Yakuhin and Novartis, consulting fees and travel support from Genentech and IQIVA, fees for serving as an expert witness from Nucleix, and fees for serving on a speakers bureau from Ono Pharma Taiwan. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients who participated in the IMbrave150 trial and their families; the investigators, nurses, and site staff; and Samantha Santangelo, Ph.D. (Health Interactions, San Francisco), for providing editorial assistance with earlier versions of the manuscript, funded by F. HoffmannâLa Roche.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1915745_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915745/suppl_file/nejmoa1915745_protocol.pdf" download="nejmoa1915745_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915745_protocol.pdf" data-doi="10.1056/NEJMoa1915745">Download</a></li><li>4.22 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1915745_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915745/suppl_file/nejmoa1915745_appendix.pdf" download="nejmoa1915745_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915745_appendix.pdf" data-doi="10.1056/NEJMoa1915745">Download</a></li><li>610.66 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1915745_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915745/suppl_file/nejmoa1915745_disclosures.pdf" download="nejmoa1915745_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915745_disclosures.pdf" data-doi="10.1056/NEJMoa1915745">Download</a></li><li>690.96 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1915745_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915745/suppl_file/nejmoa1915745_data-sharing.pdf" download="nejmoa1915745_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915745_data-sharing.pdf" data-doi="10.1056/NEJMoa1915745">Download</a></li><li>69.90 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <em>CA Cancer J Clin</em> 2018;68:394-424.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3322/caac.21492" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30207593/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450033500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries.&amp;publication_year=2018&amp;journal=CA+Cancer+J+Clin&amp;pages=394-424&amp;doi=10.3322%2Fcaac.21492&amp;pmid=30207593" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. <em>Ann Surg</em> 2001;233:236-241.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00000658-200102000-00013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11176130/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000166678300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preoperative+systemic+chemoimmunotherapy+and+sequential+resection+for+unresectable+hepatocellular+carcinoma.&amp;publication_year=2001&amp;journal=Ann+Surg&amp;pages=236-241&amp;doi=10.1097%2F00000658-200102000-00013&amp;pmid=11176130" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] liver transplantation, or ablation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease and have a poor prognosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. <em>N Engl J Med</em> 2008;359:378-390.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1915745&amp;key=10.1056%2FNEJMoa0708857&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18650514/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000257852100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sorafenib+in+advanced+hepatocellular+carcinoma.&amp;publication_year=2008&amp;journal=N+Engl+J+Med&amp;pages=378-390&amp;doi=10.1056%2FNEJMoa0708857&amp;pmid=18650514" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <em>Lancet</em> 2018;391:1163-1173.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)30207-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29433850/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428156100028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvatinib+versus+sorafenib+in+first-line+treatment+of+patients+with+unresectable+hepatocellular+carcinoma%3A+a+randomised+phase+3+non-inferiority+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=1163-1173&amp;doi=10.1016%2FS0140-6736%2818%2930207-1&amp;pmid=29433850" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] noninferiority of lenvatinib to sorafenib. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of treatment for hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <em>Lancet Oncol</em> 2018;19:940-952.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(18)30351-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29875066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000437342400053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+in+patients+with+advanced+hepatocellular+carcinoma+previously+treated+with+sorafenib+%28KEYNOTE-224%29%3A+a+non-randomised%2C+open-label+phase+2+trial.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=940-952&amp;doi=10.1016%2FS1470-2045%2818%2930351-6&amp;pmid=29875066" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] carcinoma in phase 1/2 studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the case of hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <em>Lancet</em> 2017;389:2492-2502.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)31046-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28434648/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403901800028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+in+patients+with+advanced+hepatocellular+carcinoma+%28CheckMate+040%29%3A+an+open-label%2C+non-comparative%2C+phase+1%2F2+dose+escalation+and+expansion+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=2492-2502&amp;doi=10.1016%2FS0140-6736%2817%2931046-2&amp;pmid=28434648" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. <em>J Clin Oncol</em> 2020;38:193-202.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.01307" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31790344/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508197300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+as+second-line+therapy+in+patients+with+advanced+hepatocellular+carcinoma+in+KEYNOTE-240%3A+a+randomized%2C+double-blind%2C+phase+III+trial.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=193-202&amp;doi=10.1200%2FJCO.19.01307&amp;pmid=31790344" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not significantly improve overall survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of treatment for hepatocellular carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in patients with hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). <em>Ann Oncol</em> 2019;30:Suppl 5:v874-v875. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.029" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491295500162" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CheckMate+459%3A+a+randomized%2C+multi-center+phase+3+study+of+nivolumab+%28NIVO%29+vs+sorafenib+%28SOR%29+as+first-line+%281L%29+treatment+in+patients+%28pts%29+with+advanced+hepatocellular+carcinoma+%28aHCC%29.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=v874-v875&amp;doi=10.1093%2Fannonc%2Fmdz394.029" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not significantly improve overall survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with hepatocellular carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in the case of hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. <em>Clin Cancer Res</em> 2019;25:912-920.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-18-1254" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30274981/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457395900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+angiogenesis+in+hepatocellular+carcinoma.&amp;publication_year=2019&amp;journal=Clin+Cancer+Res&amp;pages=912-920&amp;doi=10.1158%2F1078-0432.CCR-18-1254&amp;pmid=30274981" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. <em>Nat Rev Clin Oncol</em> 2011;8:292-301.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrclinonc.2011.30" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21386818/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290150100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HCC+and+angiogenesis%3A+possible+targets+and+future+directions.&amp;publication_year=2011&amp;journal=Nat+Rev+Clin+Oncol&amp;pages=292-301&amp;doi=10.1038%2Fnrclinonc.2011.30&amp;pmid=21386818" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Motz GT, Santoro SP, Wang L-P, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. <em>Nat Med</em> 2014;20:607-615.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm.3541" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24793239/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000337071000022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tumor+endothelium+FasL+establishes+a+selective+immune+barrier+promoting+tolerance+in+tumors.&amp;publication_year=2014&amp;journal=Nat+Med&amp;pages=607-615&amp;doi=10.1038%2Fnm.3541&amp;pmid=24793239" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Roland CL, Dineen SP, Lynn KD, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. <em>Mol Cancer Ther</em> 2009;8:1761-1771.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1535-7163.MCT-09-0280" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19567820/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268005700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+vascular+endothelial+growth+factor+reduces+angiogenesis+and+modulates+immune+cell+infiltration+of+orthotopic+breast+cancer+xenografts.&amp;publication_year=2009&amp;journal=Mol+Cancer+Ther&amp;pages=1761-1771&amp;doi=10.1158%2F1535-7163.MCT-09-0280&amp;pmid=19567820" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <em>J Exp Med</em> 2015;212:139-148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1084/jem.20140559" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25601652/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349549000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=VEGF-A+modulates+expression+of+inhibitory+checkpoints+on+CD8%2B+T+cells+in+tumors.&amp;publication_year=2015&amp;journal=J+Exp+Med&amp;pages=139-148&amp;doi=10.1084%2Fjem.20140559&amp;pmid=25601652" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <em>Nat Commun</em> 2016;7:12624-12624.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ncomms12624" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27571927/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384686000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+in+combination+with+bevacizumab+enhances+antigen-specific+T-cell+migration+in+metastatic+renal+cell+carcinoma.&amp;publication_year=2016&amp;journal=Nat+Commun&amp;pages=12624-12624&amp;doi=10.1038%2Fncomms12624&amp;pmid=27571927" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. <em>Semin Cancer Biol</em> 2018;52:117-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.semcancer.2017.12.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29229461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000446285900013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictive+markers+of+anti-VEGF+and+emerging+role+of+angiogenesis+inhibitors+as+immunotherapeutics.&amp;publication_year=2018&amp;journal=Semin+Cancer+Biol&amp;pages=117-124&amp;doi=10.1016%2Fj.semcancer.2017.12.002&amp;pmid=29229461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. <em>Cancer J</em> 2018;24:193-204.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/PPO.0000000000000327" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30119083/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452086500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Combinations+of+bevacizumab+with+cancer+immunotherapy.&amp;publication_year=2018&amp;journal=Cancer+J&amp;pages=193-204&amp;doi=10.1097%2FPPO.0000000000000327&amp;pmid=30119083" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with hepatocellular carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with advanced liver cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <em>Nature</em> 2014;515:563-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25428504/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346247600053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients.&amp;publication_year=2014&amp;journal=Nature&amp;pages=563-567&amp;doi=10.1038%2Fnature14011&amp;pmid=25428504" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. <em>Biochem Biophys Res Commun</em> 2005;333:328-335.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.bbrc.2005.05.132" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15961063/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230418700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bevacizumab+%28Avastin%29%2C+a+humanized+anti-VEGF+monoclonal+antibody+for+cancer+therapy.&amp;publication_year=2005&amp;journal=Biochem+Biophys+Res+Commun&amp;pages=328-335&amp;doi=10.1016%2Fj.bbrc.2005.05.132&amp;pmid=15961063" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. <em>Liver Int</em> 2009;29:284-290.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1478-3231.2008.01762.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18482274/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262284100026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+vascular+endothelial+growth+factor+with+the+monoclonal+antibody+bevacizumab+inhibits+human+hepatocellular+carcinoma+cells+growing+in+an+orthotopic+mouse+model.&amp;publication_year=2009&amp;journal=Liver+Int&amp;pages=284-290&amp;doi=10.1111%2Fj.1478-3231.2008.01762.x&amp;pmid=18482274" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. <em>J Clin Oncol</em> 2008;26:2992-2998.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2007.15.9947" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18565886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000256879700014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+trial+evaluating+the+clinical+and+biologic+effects+of+bevacizumab+in+unresectable+hepatocellular+carcinoma.&amp;publication_year=2008&amp;journal=J+Clin+Oncol&amp;pages=2992-2998&amp;doi=10.1200%2FJCO.2007.15.9947&amp;pmid=18565886" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with advanced liver cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] bevacizumab for hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. <em>Oncologist</em> 2012;17:1063-1072.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2011-0465" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22707516/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308126100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+biomarkers+of+single-agent+bevacizumab+therapy+in+patients+with+advanced+hepatocellular+carcinoma.&amp;publication_year=2012&amp;journal=Oncologist&amp;pages=1063-1072&amp;doi=10.1634%2Ftheoncologist.2011-0465&amp;pmid=22707516" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with advanced liver cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] bevacizumab for hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. <em>Expert Rev Anticancer Ther</em> 2009;9:503-509.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1586/era.09.6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19374603/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000265898300016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+angiogenesis+in+hepatocellular+carcinoma%3A+focus+on+VEGF+and+bevacizumab.&amp;publication_year=2009&amp;journal=Expert+Rev+Anticancer+Ther&amp;pages=503-509&amp;doi=10.1586%2Fera.09.6&amp;pmid=19374603" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Lee MS, Ryoo B-Y, Hsu C-H, et al. Randomised efficacy and safety results for atezolizumab (ATEZO) + bevacizumab (BEV) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). <em>Ann Oncol</em> 2019;30:Suppl 5:v875-v875. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.030" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30993330/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479284000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomised+efficacy+and+safety+results+for+atezolizumab+%28ATEZO%29+%2B+bevacizumab+%28BEV%29+in+patients+%28pts%29+with+previously+untreated%2C+unresectable+hepatocellular+carcinoma+%28HCC%29.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=v875-v875&amp;doi=10.1093%2Fannonc%2Fmdz394.030&amp;pmid=30993330" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] progression-free survival of 7 months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] signaling in unresectable liver cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than with monotherapy with atezolizumab, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in the case of hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. <em>Hepatology</em> 2018;68:723-750.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.29913" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29624699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000441244400029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis%2C+staging%2C+and+management+of+hepatocellular+carcinoma%3A+2018+practice+guidance+by+the+American+Association+for+the+Study+of+Liver+Diseases.&amp;publication_year=2018&amp;journal=Hepatology&amp;pages=723-750&amp;doi=10.1002%2Fhep.29913&amp;pmid=29624699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. <em>Semin Liver Dis</em> 2010;30:52-60.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0030-1247132" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20175033/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000274665100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Modified+RECIST+%28mRECIST%29+assessment+for+hepatocellular+carcinoma.&amp;publication_year=2010&amp;journal=Semin+Liver+Dis&amp;pages=52-60&amp;doi=10.1055%2Fs-0030-1247132&amp;pmid=20175033" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. <em>Stat Med</em> 2009;28:586-604.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.3495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19051220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263005700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+graphical+approach+to+sequentially+rejective+multiple+test+procedures.&amp;publication_year=2009&amp;journal=Stat+Med&amp;pages=586-604&amp;doi=10.1002%2Fsim.3495&amp;pmid=19051220" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. <em>Hepatology</em> 2016;64:2038-2046.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.28710" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27359084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393900200059" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Programmed+death+ligand+1+expression+in+hepatocellular+carcinoma%3A+relationship+with+clinical+and+pathological+features.&amp;publication_year=2016&amp;journal=Hepatology&amp;pages=2038-2046&amp;doi=10.1002%2Fhep.28710&amp;pmid=27359084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <em>Lancet</em> 2019;393:2404-2415.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)30723-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31079938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471758200038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+plus+bevacizumab+versus+sunitinib+in+patients+with+previously+untreated+metastatic+renal+cell+carcinoma+%28IMmotion151%29%3A+a+multicentre%2C+open-label%2C+phase+3%2C+randomised+controlled+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2404-2415&amp;doi=10.1016%2FS0140-6736%2819%2930723-8&amp;pmid=31079938" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/20"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">20</span></span> â¢ <span property="datePublished">May 14, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1894</span>-<span property="pageEnd">1905</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa1915745" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa1915745?sg=AbW1N">Chinese Translation ä¸­æç¿»è¯</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: May 13, 2020</div><div><b class="core-label">Published in issue</b>: May 14, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/liver-disease" alt="View article keyword Liver Disease" data-interactiontype="article_recirculation_click">Liver Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Richard S.</span> <span property="familyName">Finn</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shukui</span> <span property="familyName">Qin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Masafumi</span> <span property="familyName">Ikeda</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter R.</span> <span property="familyName">Galle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michel</span> <span property="familyName">Ducreux</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tae-You</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Masatoshi</span> <span property="familyName">Kudo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Valeriy</span> <span property="familyName">Breder</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philippe</span> <span property="familyName">Merle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ahmed O.</span> <span property="familyName">Kaseb</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daneng</span> <span property="familyName">Li</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wendy</span> <span property="familyName">Verret</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Derek-Zhen</span> <span property="familyName">Xu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sairy</span> <span property="familyName">Hernandez</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Juan</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chen</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sohail</span> <span property="familyName">Mulla</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yulei</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ho Yeong</span> <span property="familyName">Lim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew X.</span> <span property="familyName">Zhu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Ann-Lii</span> <span property="familyName">Cheng</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the IMbrave150 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles (R.S.F.), the City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte (D.L.), and Genentech, South San Francisco (W.V., S.H., Y.W.) â all in California; the Peopleâs Liberation Army Cancer Center, Jinling Hospital, Nanjing (S.Q.), and Roche Product Development (D.-Z.X., J.L., C.H.) and Jiahui International Cancer Center, Jiahui Health (A.X.Z.), Shanghai â all in China; National Cancer Center Hospital East, Kashiwa (M.I.), and Kindai University Faculty of Medicine, Osaka (M.K.) â both in Japan; University Medical Center Mainz, Mainz, Germany (P.R.G.); Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif (M.D.), and University Hospital La Croix-Rousse, Lyon (P.M.) â both in France; Seoul National University College of Medicine (T.-Y.K.) and Samsung Medical Center, Sungkyunkwan University School of Medicine (H.Y.L.) â both in Seoul, South Korea; N.N. Blokhin Russian Cancer Research Center, Moscow (V.B.); the University of Texas M.D. Anderson Cancer Center, Houston (A.O.K.); HoffmannâLa Roche, Mississauga, ON, Canada (S.M.); Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston (A.X.Z.); and the National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei (A.-L.C.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Cheng at the National Taiwan University Cancer Center and National Taiwan University Hospital, 7 Chung-Shan South Rd., Taipei, 10002, Taiwan, or at <a href="mailto:alcheng@ntu.edu.tw">alcheng@ntu.edu.tw</a>; or to Dr. Finn at the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, 2825 Santa Monica Blvd., Suite 200, Santa Monica, CA, 90404, or at <a href="mailto:rfinn@mednet.ucla.edu">rfinn@mednet.ucla.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A list of the IMbrave150 trial investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">4894</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1915745" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="20ba4077-4ba1-aed3-9e99-cbd82b16e763"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1064" src="https://badges.altmetric.com/?size=320&amp;score=1064&amp;types=mabvctwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_20ba4077-4ba1-aed3-9e99-cbd82b16e763" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=news">
          Picked up by <b>100</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=blogs">
          Blogged by <b>8</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=twitter">
          Posted by <b>389</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=patents">
          Referenced in <b>4</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=wikipedia">
          Referenced in <b>3</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=video">
          On <b>2</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=81978554&amp;tab=guidelines">
          Referenced in <b>16</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>2014</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d62b01425af1d2-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1915745"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-20%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1915745%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="4894" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jiayun Jiang, </li><li class="list-inline-item cited-by__entry__author">Hui Zhang, </li><li class="list-inline-item cited-by__entry__author">Yanjiao Ou, </li><li class="list-inline-item cited-by__entry__author">Jiejuan Lai, </li><li class="list-inline-item cited-by__entry__author">Yulan Huang, </li><li class="list-inline-item cited-by__entry__author">Wenyun Cai, </li><li class="list-inline-item cited-by__entry__author">Chong Li, </li><li class="list-inline-item cited-by__entry__author">Leida Zhang, </li><li class="list-inline-item cited-by__entry__author">Yu Fu, </li></ul><span class="cited-by__entry__title">The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment, </span><span class="cited-by__entry__series-title">Immunology Letters, </span><span class="cited-by__entry__volume"><strong>275</strong>, </span><span class="cited-by__entry__page-range">(107003), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.imlet.2025.107003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.imlet.2025.107003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.imlet.2025.107003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Gaofeng Liu, </li><li class="list-inline-item cited-by__entry__author">Shanshan Kuang, </li><li class="list-inline-item cited-by__entry__author">Weixing Zhong, </li><li class="list-inline-item cited-by__entry__author">Anming Yang, </li><li class="list-inline-item cited-by__entry__author">Xiaoli Huang, </li><li class="list-inline-item cited-by__entry__author">Yin Xie, </li><li class="list-inline-item cited-by__entry__author">Xin Zhang, </li><li class="list-inline-item cited-by__entry__author">Yikai Li, </li><li class="list-inline-item cited-by__entry__author">Qingguang Qin, </li><li class="list-inline-item cited-by__entry__author">Guangjie Liu, </li></ul><span class="cited-by__entry__title">Exploring the potential mechanisms of Jinglinzi powder in treating hepatocellular carcinoma based on LC-MS, network pharmacology, molecular docking, and experimental validation, </span><span class="cited-by__entry__series-title">Journal of Pharmaceutical and Biomedical Analysis, </span><span class="cited-by__entry__volume"><strong>263</strong>, </span><span class="cited-by__entry__page-range">(116899), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jpba.2025.116899" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jpba.2025.116899</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jpba.2025.116899" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Karan Kumar, </li><li class="list-inline-item cited-by__entry__author">Vivek A. Saraswat, </li></ul><span class="cited-by__entry__title">Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025, </span><span class="cited-by__entry__series-title">Journal of Clinical and Experimental Hepatology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(102547), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jceh.2025.102547" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jceh.2025.102547</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jceh.2025.102547" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kulvinder Kaur, </li><li class="list-inline-item cited-by__entry__author">Parag Jain, </li><li class="list-inline-item cited-by__entry__author">Dinesh Kumar Chelike, </li><li class="list-inline-item cited-by__entry__author">undefined Ajazuddin, </li></ul><span class="cited-by__entry__title">Heterocyclic compounds in targeted treatment of hepatocellular Carcinoma: Mechanistic Insights and clinical Implications, </span><span class="cited-by__entry__series-title">Inorganic Chemistry Communications, </span><span class="cited-by__entry__volume"><strong>179</strong>, </span><span class="cited-by__entry__page-range">(114704), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.inoche.2025.114704" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.inoche.2025.114704</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.inoche.2025.114704" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mao-Yuan Mu, </li><li class="list-inline-item cited-by__entry__author">Zi-Xiong Chen, </li><li class="list-inline-item cited-by__entry__author">Yu-Zhe Cao, </li><li class="list-inline-item cited-by__entry__author">Xiao-Bo Fu, </li><li class="list-inline-item cited-by__entry__author">Li-Jie Qiu, </li><li class="list-inline-item cited-by__entry__author">Han Qi, </li><li class="list-inline-item cited-by__entry__author">Fei Gao, </li></ul><span class="cited-by__entry__title">Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study, </span><span class="cited-by__entry__series-title">Cancer Letters, </span><span class="cited-by__entry__volume"><strong>628</strong>, </span><span class="cited-by__entry__page-range">(217851), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.canlet.2025.217851" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.canlet.2025.217851</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.canlet.2025.217851" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nasha Qiu, </li><li class="list-inline-item cited-by__entry__author">Chang Xu, </li><li class="list-inline-item cited-by__entry__author">Zhen Zhang, </li><li class="list-inline-item cited-by__entry__author">Rui Wang, </li><li class="list-inline-item cited-by__entry__author">Xuyong Wei, </li><li class="list-inline-item cited-by__entry__author">Yangla Xie, </li><li class="list-inline-item cited-by__entry__author">Shuai Wang, </li><li class="list-inline-item cited-by__entry__author">Di Lu, </li><li class="list-inline-item cited-by__entry__author">Kai Wang, </li><li class="list-inline-item cited-by__entry__author">Shengjun Xu, </li><li class="list-inline-item cited-by__entry__author">Chenchen Shen, </li><li class="list-inline-item cited-by__entry__author">Renyi Su, </li><li class="list-inline-item cited-by__entry__author">Beini Cen, </li><li class="list-inline-item cited-by__entry__author">Yanpeng Liu, </li><li class="list-inline-item cited-by__entry__author">Youqing Shen, </li><li class="list-inline-item cited-by__entry__author">Xiao Xu, </li></ul><span class="cited-by__entry__title">Autologous tumoral esterase-driven therapeutic polymers sequentially orchestrated antigen-induction, STING activation and anti-angiogenesis for systemic cancer immune therapy, </span><span class="cited-by__entry__series-title">Biomaterials, </span><span class="cited-by__entry__volume"><strong>320</strong>, </span><span class="cited-by__entry__page-range">(123260), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.biomaterials.2025.123260" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.biomaterials.2025.123260</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.biomaterials.2025.123260" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ting Luo, </li><li class="list-inline-item cited-by__entry__author">Kunpeng Ma, </li><li class="list-inline-item cited-by__entry__author">Yi Zhang, </li><li class="list-inline-item cited-by__entry__author">Qingwen Xue, </li><li class="list-inline-item cited-by__entry__author">Jie Yu, </li><li class="list-inline-item cited-by__entry__author">Xing-Jie Liang, </li><li class="list-inline-item cited-by__entry__author">Ping Liang, </li></ul><span class="cited-by__entry__title">Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity, </span><span class="cited-by__entry__series-title">Bioactive Materials, </span><span class="cited-by__entry__volume"><strong>51</strong>, </span><span class="cited-by__entry__page-range">(634-649), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bioactmat.2025.05.016" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bioactmat.2025.05.016</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bioactmat.2025.05.016" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Francesco Vitiello, </li><li class="list-inline-item cited-by__entry__author">Toshifumi Tada, </li><li class="list-inline-item cited-by__entry__author">Goki Suda, </li><li class="list-inline-item cited-by__entry__author">Shigeo Shimose, </li><li class="list-inline-item cited-by__entry__author">Masatoshi Kudo, </li><li class="list-inline-item cited-by__entry__author">Jaekyung Cheon, </li><li class="list-inline-item cited-by__entry__author">Fabian Finkelmeier, </li><li class="list-inline-item cited-by__entry__author">Ho Yeong Lim, </li><li class="list-inline-item cited-by__entry__author">JosÃ© Presa, </li><li class="list-inline-item cited-by__entry__author">Gianluca Masi, </li><li class="list-inline-item cited-by__entry__author">Changhoon Yoo, </li><li class="list-inline-item cited-by__entry__author">Sara Lonardi, </li><li class="list-inline-item cited-by__entry__author">Francesco Tovoli, </li><li class="list-inline-item cited-by__entry__author">Takashi Kumada, </li><li class="list-inline-item cited-by__entry__author">Mario Scartozzi, </li><li class="list-inline-item cited-by__entry__author">Emiliano Tamburini, </li><li class="list-inline-item cited-by__entry__author">Francesco Giuseppe Foschi, </li><li class="list-inline-item cited-by__entry__author">Mara Persano, </li><li class="list-inline-item cited-by__entry__author">Federico Rossari, </li><li class="list-inline-item cited-by__entry__author">Silvia Foti, </li><li class="list-inline-item cited-by__entry__author">Silvia Camera, </li><li class="list-inline-item cited-by__entry__author">Francesco De Cobelli, </li><li class="list-inline-item cited-by__entry__author">Luca Aldrighetti, </li><li class="list-inline-item cited-by__entry__author">Stefano Cascinu, </li><li class="list-inline-item cited-by__entry__author">Andrea Casadei-Gardini, </li><li class="list-inline-item cited-by__entry__author">Margherita Rimini, </li></ul><span class="cited-by__entry__title">Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population, </span><span class="cited-by__entry__series-title">Seminars in Oncology, </span><span class="cited-by__entry__volume"><strong>52</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(152348), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.seminoncol.2025.152348" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.seminoncol.2025.152348</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.seminoncol.2025.152348" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yixiao Jiang, </li><li class="list-inline-item cited-by__entry__author">Ze Yu, </li><li class="list-inline-item cited-by__entry__author">Jie Wang, </li><li class="list-inline-item cited-by__entry__author">Yixin Wu, </li><li class="list-inline-item cited-by__entry__author">Ziqi Li, </li><li class="list-inline-item cited-by__entry__author">Ting Le, </li><li class="list-inline-item cited-by__entry__author">Chen Yang, </li><li class="list-inline-item cited-by__entry__author">Yalong Wei, </li><li class="list-inline-item cited-by__entry__author">Guoqiang Zhang, </li><li class="list-inline-item cited-by__entry__author">Haijie Ma, </li></ul><span class="cited-by__entry__title">Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1, </span><span class="cited-by__entry__series-title">International Immunopharmacology, </span><span class="cited-by__entry__volume"><strong>161</strong>, </span><span class="cited-by__entry__page-range">(115024), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.intimp.2025.115024" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.intimp.2025.115024</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.intimp.2025.115024" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Caique Mariano Pedroso, </li><li class="list-inline-item cited-by__entry__author">Mariana de Pauli Paglioni, </li><li class="list-inline-item cited-by__entry__author">Ana Gabriela Costa Normando, </li><li class="list-inline-item cited-by__entry__author">Aline Lauda Freitas Chaves, </li><li class="list-inline-item cited-by__entry__author">Luiz Paulo Kowalski, </li><li class="list-inline-item cited-by__entry__author">Gilberto de Castro JÃºnior, </li><li class="list-inline-item cited-by__entry__author">Leandro Luongo Matos, </li><li class="list-inline-item cited-by__entry__author">William Nassib Willian Junior, </li><li class="list-inline-item cited-by__entry__author">Thiago Bueno de Oliveira, </li><li class="list-inline-item cited-by__entry__author">Pedro de Marchi, </li><li class="list-inline-item cited-by__entry__author">Guilherme Harada, </li><li class="list-inline-item cited-by__entry__author">Milena Perez Mak, </li><li class="list-inline-item cited-by__entry__author">Carmen Silvia Passos Lima, </li><li class="list-inline-item cited-by__entry__author">Gustavo Arruda Viani, </li><li class="list-inline-item cited-by__entry__author">Fabio Ynoe Moraes, </li><li class="list-inline-item cited-by__entry__author">Andre Guimaraes Gouveia, </li><li class="list-inline-item cited-by__entry__author">Alan Roger Santos-Silva, </li><li class="list-inline-item cited-by__entry__author">Gustavo Nader Marta, </li></ul><span class="cited-by__entry__title">Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>212</strong>, </span><span class="cited-by__entry__page-range">(104742), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104742" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104742</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104742" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-20%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1915745%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1915745" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1915745.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f1.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/3eb2d908-01f0-4fc5-9e75-c18c7ab8aa6d/assets/images/large/nejmoa1915745_f1.jpg" height="2370" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">KaplanâMeier Analysis of Overall and Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival (Panel A) and progression-free survival (Panel B), as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1, for patients in the intention-to-treat population. Stratified hazard ratios for progression or death are reported, along with P values. The two-sided P-value boundary calculated on the basis of 161 deaths is 0.0033. Randomization was performed through an interactive voice-response or Web-response system, and factors included in the stratified P value and Cox model were geographic region (Asia [excluding Japan] vs. the rest of the world), alpha-fetoprotein level at baseline (&lt;400 ng per milliliter vs. â¥400 ng per milliliter), and macrovascular invasion, extrahepatic spread, or both (yes vs. no). Tick marks indicate censored data. CI denotes confidence interval, and NE could not be evaluated.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f2.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/b59fbc43-f19b-4c1c-973c-cd57aa78c40e/assets/images/large/nejmoa1915745_f2.jpg" height="1331" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">KaplanâMeier Analysis of Time to Deterioration of Quality of Life.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of the time to deterioration in quality of life in the intention-to-treat population. Tick marks indicate censored data.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915745/asset/4ce30c5d-9695-4edb-8010-151ce4a7f2c2/assets/images/large/nejmoa1915745_t1.jpg" height="2375" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">AtezolizumabâBevacizumab<br>(N=336)</th><th class="txxr-borders">Sorafenib<br>(N=165)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) â yr</td><td class="xxxx-borders shading">64 (56â71)</td><td class="xxxr-borders shading">66 (59â71)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">277 (82)</td><td class="xxxr-borders">137 (83)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Geographic region â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asia, excluding Japan</td><td class="xxxx-borders">133 (40)</td><td class="xxxr-borders">68 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Rest of the world<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">203 (60)</td><td class="xxxr-borders shading">97 (59)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ECOG performance status score â no. (%)<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">209 (62)</td><td class="xxxr-borders shading">103 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">127 (38)</td><td class="xxxr-borders">62 (38)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ChildâPugh classification â no./total no. (%)<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">A5</td><td class="xxxx-borders">239/333 (72)</td><td class="xxxr-borders">121/165 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">A6</td><td class="xxxx-borders shading">94/333 (28)</td><td class="xxxr-borders shading">44/165 (27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Barcelona Clinic liver cancer stage â no. (%)<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">A</td><td class="xxxx-borders shading">8 (2)</td><td class="xxxr-borders shading">6 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">B</td><td class="xxxx-borders">52 (15)</td><td class="xxxr-borders">26 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">276 (82)</td><td class="xxxr-borders shading">133 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Alpha-fetoprotein â¥400 ng per milliliter â no. (%)</td><td class="xxxx-borders">126 (38)</td><td class="xxxr-borders">61 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Presence of macrovascular invasion, extrahepatic spread, or both â no. (%)</td><td class="xxxx-borders shading">258 (77)</td><td class="xxxr-borders shading">120 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Macrovascular invasion</td><td class="xxxx-borders">129 (38)</td><td class="xxxr-borders">71 (43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Extrahepatic spread</td><td class="xxxx-borders shading">212 (63)</td><td class="xxxr-borders shading">93 (56)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Varices â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Present at baseline</td><td class="xxxx-borders shading">88 (26)</td><td class="xxxr-borders shading">43 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Treated at baseline</td><td class="xxxx-borders">36 (11)</td><td class="xxxr-borders">23 (14)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Cause of hepatocellular carcinoma â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hepatitis B</td><td class="xxxx-borders">164 (49)</td><td class="xxxr-borders">76 (46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hepatitis C</td><td class="xxxx-borders shading">72 (21)</td><td class="xxxr-borders shading">36 (22)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonviral<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">100 (30)</td><td class="xxxr-borders">53 (32)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Prior local therapy for hepatocellular carcinoma â no. (%)</td><td class="xbxx-borders shading">161 (48)</td><td class="xbxr-borders shading">85 (52)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Percentages may not total 100 because of rounding. IQR denotes interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The rest of the world includes the United States, Australia, New Zealand, and Japan.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5, with higher numbers reflecting greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The ChildâPugh liver function scale is a three-category scale (A, with scores of 5 or 6, indicating good hepatic function; B, with scores of 7 to 9, indicating moderately impaired hepatic function; or C, with scores of 10 to 15, indicating advanced hepatic dysfunction). Classification is determined by scoring according to the presence and severity of five clinical measures of liver disease (encephalopathy, ascites, bilirubin levels, albumin levels, and prolonged prothrombin time). Data shown reflect patients in Class A with scores of 5 or 6 and thus good hepatic function. Precise numeric scores for two patients in the atezolizumabâbevacizumab group who were in Class A on the ChildâPugh scale were not available. Data are not included for one patient in the atezolizumabâbevacizumab group whose classification was B7.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The Barcelona Clinic liver cancer staging system ranks hepatocellular carcinoma in 5 stages, beginning at 0 (very early stage) and progressing from A (early stage) to D (terminal stage).</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Nonviral causes include alcohol, other, and unknown non-hepatitis B and C causes.</div></div></div></figcaption></a><figcaption><div class="caption">Patient Characteristics at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915745/asset/43d53d04-117f-49fc-9fc1-d850d7664c36/assets/images/large/nejmoa1915745_t2.jpg" height="1262" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>RECIST 1.1</span></th><th class="txxr-borders" colspan="3"><span>HCC-Specific mRECIST</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">AtezolizumabâBevacizumab<br>(N=326)</th><th class="xxxx-borders">Sorafenib<br>(N=159)</th><th class="xxxx-borders">Difference<br>(P Value)<a href="#core-t2fn2" role="doc-noteref">â </a></th><th class="xxxx-borders">AtezolizumabâBevacizumab<br>(N=325)</th><th class="xxxx-borders">Sorafenib<br>(N=158)</th><th class="xxxr-borders">Difference<br>(P Value)<a href="#core-t2fn2" role="doc-noteref">â </a></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confirmed objective response â no. (% [95% CI])<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">89<br>(27.3 [22.5â32.5])</td><td class="xxxx-borders shading">19<br>(11.9 [7.4â18.0])</td><td class="xxxx-borders shading">15.4<br> (&lt;0.001)</td><td class="xxxx-borders shading">108<br>(33.2 [28.1â38.6])</td><td class="xxxx-borders shading">21<br>(13.3 [8.4â19.6])</td><td class="xxxr-borders shading">19.9<br>(&lt;0.001)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response â no. (%)</td><td class="xxxx-borders">18 (5.5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">33 (10.2)</td><td class="xxxx-borders">3 (1.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response â no. (%)</td><td class="xxxx-borders shading">71 (21.8)</td><td class="xxxx-borders shading">19 (11.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">75 (23.1)</td><td class="xxxx-borders shading">18 (11.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Stable disease â no. (%)</td><td class="xxxx-borders">151 (46.3)</td><td class="xxxx-borders">69 (43.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">127 (39.1)</td><td class="xxxx-borders">66 (41.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Disease control rate â no. (%)<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">240 (73.6)</td><td class="xxxx-borders shading">88 (55.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">235 (72.3)</td><td class="xxxx-borders shading">87 (55.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Progressive disease â no. (%)</td><td class="xxxx-borders">64 (19.6)</td><td class="xxxx-borders">39 (24.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">66 (20.3)</td><td class="xxxx-borders">40 (25.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Could not be evaluated â no. (%)</td><td class="xxxx-borders shading">8 (2.5)</td><td class="xxxx-borders shading">14 (8.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">10 (3.1)</td><td class="xxxx-borders shading">14 (8.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Data missing â no. (%)</td><td class="xxxx-borders">14 (4.3)</td><td class="xxxx-borders">18 (11.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">14 (4.3)</td><td class="xxxx-borders">17 (10.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Ongoing objective response at data cutoff â no./total no. (%)</td><td class="xbxx-borders shading">77/89 (86.5)</td><td class="xbxx-borders shading">13/19 (68.4)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">84/108 (77.8)</td><td class="xbxx-borders shading">13/21 (61.9)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Included are patients who presented with measurable disease according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), and according to hepatocellular carcinoma (HCC)âspecific modified RECIST (mRECIST), as assessed at an independent review facility. CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The difference is the between-group difference (atezolizumabâbevacizumab minus sorafenib) in the percentage of patients with confirmed response, expressed in percentage points. The P value was derived from a CochranâMantelâHaenszel test. Randomization, which was performed through an interactive voice-response or Web-response system, included as stratification factors geographic region (Asia excluding Japan vs. the rest of the world), alpha-fetoprotein level (&lt;400 ng per milliliter vs. â¥400 ng per milliliter) at baseline, and macrovascular invasion, extrahepatic spread, or both (yes vs. no).</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Confirmed objective response was defined as a response (complete or partial) seen at two consecutive tumor assessments at least 28 days apart.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The control rate is the sum of complete response, partial response, and stable disease.</div></div></div></figcaption></a><figcaption><div class="caption">Secondary Efficacy Outcomes.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915745/asset/5bb5bd8d-0d1f-449c-8c5d-252bf5ba113e/assets/images/large/nejmoa1915745_t3.jpg" height="1152" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">AtezolizumabâBevacizumab<br>(N=329)</th><th class="txxr-borders">Sorafenib<br>(N=156)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients with an adverse event from any cause</td><td class="xxxx-borders shading">323 (98.2)</td><td class="xxxr-borders shading">154 (98.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Grade 3 or 4 event<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">186 (56.5)</td><td class="xxxr-borders">86 (55.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Grade 5 event<a href="#core-t3fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">15 (4.6)</td><td class="xxxr-borders shading">9 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders">125 (38.0)</td><td class="xxxr-borders">48 (30.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to withdrawal from any trial drug</td><td class="xxxx-borders shading">51 (15.5)</td><td class="xxxr-borders shading">16 (10.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Withdrawal from atezolizumabâbevacizumab</td><td class="xxxx-borders">23 (7.0)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to dose modification or interruption of any trial drug</td><td class="xxxx-borders shading">163 (49.5)</td><td class="xxxr-borders shading">95 (60.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dose interruption of any trial treatment</td><td class="xxxx-borders">163 (49.5)</td><td class="xxxr-borders">64 (41.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Dose modification of sorafenib</td><td class="xbxx-borders shading">â</td><td class="xbxr-borders shading">58 (37.2)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Numbers represent the highest grades assigned.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Grade 5 events in the atezolizumabâbevacizumab group included gastrointestinal hemorrhage (in 3 patients), pneumonia (in 2 patients), empyema, gastric ulcer perforation, abnormal hepatic function, liver injury, multiple-organ dysfunction syndrome, esophageal varices hemorrhage, subarachnoid hemorrhage, respiratory distress, sepsis, and cardiac arrest (in 1 patient each); grade 5 events in the sorafenib group included death (in 2 patients), hepatic cirrhosis (in 2 patients), cardiac arrest, cardiac failure, general physical health deterioration, hepatitis E, and peritoneal hemorrhage (in 1 patient each).</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events from Any Cause.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t4"><figure class="table"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t4.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915745/asset/601a5728-455c-47b6-af09-a831c78632c7/assets/images/large/nejmoa1915745_t4.jpg" height="1688" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>AtezolizumabâBevacizumab<br>(N=329)</span></th><th class="txxr-borders" colspan="2"><span>Sorafenib<br>(N=156)</span></th></tr><tr class="head2" data-type="row head2" data-xml-valign="top"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">98 (29.8)</td><td class="xxxx-borders shading">50 (15.2)</td><td class="xxxx-borders shading">38 (24.4)</td><td class="xxxr-borders shading">19 (12.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">67 (20.4)</td><td class="xxxx-borders">8 (2.4)</td><td class="xxxx-borders">29 (18.6)</td><td class="xxxr-borders">5 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Proteinuria</td><td class="xxxx-borders shading">66 (20.1)</td><td class="xxxx-borders shading">10 (3.0)</td><td class="xxxx-borders shading">11 (7.1)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Aspartate aminotransferase increase</td><td class="xxxx-borders">64 (19.5)</td><td class="xxxx-borders">23 (7.0)</td><td class="xxxx-borders">26 (16.7)</td><td class="xxxr-borders">8 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">64 (19.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (9.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">62 (18.8)</td><td class="xxxx-borders">6 (1.8)</td><td class="xxxx-borders">77 (49.4)</td><td class="xxxr-borders">8 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">58 (17.6)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">38 (24.4)</td><td class="xxxr-borders shading">6 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">59 (17.9)</td><td class="xxxx-borders">4 (1.2)</td><td class="xxxx-borders">15 (9.6)</td><td class="xxxr-borders">2 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Alanine aminotransferase increase</td><td class="xxxx-borders shading">46 (14.0)</td><td class="xxxx-borders shading">12 (3.6)</td><td class="xxxx-borders shading">14 (9.0)</td><td class="xxxr-borders shading">2 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">44 (13.4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">22 (14.1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Blood bilirubin increase</td><td class="xxxx-borders shading">43 (13.1)</td><td class="xxxx-borders shading">8 (2.4)</td><td class="xxxx-borders shading">22 (14.1)</td><td class="xxxr-borders shading">10 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Rash</td><td class="xxxx-borders">41 (12.5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">27 (17.3)</td><td class="xxxr-borders">4 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders shading">40 (12.2)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">27 (17.3)</td><td class="xxxr-borders shading">4 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">40 (12.2)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">25 (16.0)</td><td class="xxxr-borders">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cough</td><td class="xxxx-borders shading">39 (11.9)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (9.6)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Infusion-related reaction</td><td class="xxxx-borders">37 (11.2)</td><td class="xxxx-borders">8 (2.4)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Weight decrease</td><td class="xxxx-borders shading">37 (11.2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (9.6)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Platelet count decrease</td><td class="xxxx-borders">35 (10.6)</td><td class="xxxx-borders">11 (3.3)</td><td class="xxxx-borders">18 (11.5)</td><td class="xxxr-borders">2 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Epistaxis</td><td class="xxxx-borders shading">34 (10.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (4.5)</td><td class="xxxr-borders shading">1 (0.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Asthenia</td><td class="xxxx-borders">22 (6.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">21 (13.5)</td><td class="xxxr-borders">4 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Alopecia</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">22 (14.1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Palmarâplantar erythrodysesthesia syndrome</td><td class="xbxx-borders">3 (0.9)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">75 (48.1)</td><td class="xbxr-borders">13 (8.3)</td></tr></tbody></table></div></a><figcaption>Adverse Events with an Incidence of More Than 10% in Either Group.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t4"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915745_t4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1915745</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <em>CA Cancer J Clin</em> 2018;68:394-424.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3322/caac.21492" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30207593/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450033500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries.&amp;publication_year=2018&amp;journal=CA+Cancer+J+Clin&amp;pages=394-424&amp;doi=10.3322%2Fcaac.21492&amp;pmid=30207593" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. <em>Ann Surg</em> 2001;233:236-241.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00000658-200102000-00013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11176130/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000166678300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preoperative+systemic+chemoimmunotherapy+and+sequential+resection+for+unresectable+hepatocellular+carcinoma.&amp;publication_year=2001&amp;journal=Ann+Surg&amp;pages=236-241&amp;doi=10.1097%2F00000658-200102000-00013&amp;pmid=11176130" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] liver transplantation, or ablation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease and have a poor prognosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. <em>N Engl J Med</em> 2008;359:378-390.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1915745&amp;key=10.1056%2FNEJMoa0708857&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18650514/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000257852100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sorafenib+in+advanced+hepatocellular+carcinoma.&amp;publication_year=2008&amp;journal=N+Engl+J+Med&amp;pages=378-390&amp;doi=10.1056%2FNEJMoa0708857&amp;pmid=18650514" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <em>Lancet</em> 2018;391:1163-1173.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)30207-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29433850/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428156100028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lenvatinib+versus+sorafenib+in+first-line+treatment+of+patients+with+unresectable+hepatocellular+carcinoma%3A+a+randomised+phase+3+non-inferiority+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=1163-1173&amp;doi=10.1016%2FS0140-6736%2818%2930207-1&amp;pmid=29433850" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] noninferiority of lenvatinib to sorafenib. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of treatment for hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <em>Lancet Oncol</em> 2018;19:940-952.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(18)30351-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29875066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000437342400053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+in+patients+with+advanced+hepatocellular+carcinoma+previously+treated+with+sorafenib+%28KEYNOTE-224%29%3A+a+non-randomised%2C+open-label+phase+2+trial.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=940-952&amp;doi=10.1016%2FS1470-2045%2818%2930351-6&amp;pmid=29875066" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] carcinoma in phase 1/2 studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the case of hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <em>Lancet</em> 2017;389:2492-2502.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)31046-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28434648/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403901800028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+in+patients+with+advanced+hepatocellular+carcinoma+%28CheckMate+040%29%3A+an+open-label%2C+non-comparative%2C+phase+1%2F2+dose+escalation+and+expansion+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=2492-2502&amp;doi=10.1016%2FS0140-6736%2817%2931046-2&amp;pmid=28434648" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. <em>J Clin Oncol</em> 2020;38:193-202.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.01307" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31790344/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508197300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+as+second-line+therapy+in+patients+with+advanced+hepatocellular+carcinoma+in+KEYNOTE-240%3A+a+randomized%2C+double-blind%2C+phase+III+trial.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=193-202&amp;doi=10.1200%2FJCO.19.01307&amp;pmid=31790344" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not significantly improve overall survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of treatment for hepatocellular carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in patients with hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). <em>Ann Oncol</em> 2019;30:Suppl 5:v874-v875. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.029" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491295500162" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CheckMate+459%3A+a+randomized%2C+multi-center+phase+3+study+of+nivolumab+%28NIVO%29+vs+sorafenib+%28SOR%29+as+first-line+%281L%29+treatment+in+patients+%28pts%29+with+advanced+hepatocellular+carcinoma+%28aHCC%29.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=v874-v875&amp;doi=10.1093%2Fannonc%2Fmdz394.029" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not significantly improve overall survival. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with hepatocellular carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in the case of hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. <em>Clin Cancer Res</em> 2019;25:912-920.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-18-1254" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30274981/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457395900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+angiogenesis+in+hepatocellular+carcinoma.&amp;publication_year=2019&amp;journal=Clin+Cancer+Res&amp;pages=912-920&amp;doi=10.1158%2F1078-0432.CCR-18-1254&amp;pmid=30274981" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. <em>Nat Rev Clin Oncol</em> 2011;8:292-301.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrclinonc.2011.30" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21386818/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290150100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HCC+and+angiogenesis%3A+possible+targets+and+future+directions.&amp;publication_year=2011&amp;journal=Nat+Rev+Clin+Oncol&amp;pages=292-301&amp;doi=10.1038%2Fnrclinonc.2011.30&amp;pmid=21386818" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Motz GT, Santoro SP, Wang L-P, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. <em>Nat Med</em> 2014;20:607-615.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm.3541" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24793239/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000337071000022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tumor+endothelium+FasL+establishes+a+selective+immune+barrier+promoting+tolerance+in+tumors.&amp;publication_year=2014&amp;journal=Nat+Med&amp;pages=607-615&amp;doi=10.1038%2Fnm.3541&amp;pmid=24793239" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Roland CL, Dineen SP, Lynn KD, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. <em>Mol Cancer Ther</em> 2009;8:1761-1771.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1535-7163.MCT-09-0280" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19567820/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268005700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+vascular+endothelial+growth+factor+reduces+angiogenesis+and+modulates+immune+cell+infiltration+of+orthotopic+breast+cancer+xenografts.&amp;publication_year=2009&amp;journal=Mol+Cancer+Ther&amp;pages=1761-1771&amp;doi=10.1158%2F1535-7163.MCT-09-0280&amp;pmid=19567820" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <em>J Exp Med</em> 2015;212:139-148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1084/jem.20140559" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25601652/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349549000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=VEGF-A+modulates+expression+of+inhibitory+checkpoints+on+CD8%2B+T+cells+in+tumors.&amp;publication_year=2015&amp;journal=J+Exp+Med&amp;pages=139-148&amp;doi=10.1084%2Fjem.20140559&amp;pmid=25601652" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <em>Nat Commun</em> 2016;7:12624-12624.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ncomms12624" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27571927/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384686000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+in+combination+with+bevacizumab+enhances+antigen-specific+T-cell+migration+in+metastatic+renal+cell+carcinoma.&amp;publication_year=2016&amp;journal=Nat+Commun&amp;pages=12624-12624&amp;doi=10.1038%2Fncomms12624&amp;pmid=27571927" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. <em>Semin Cancer Biol</em> 2018;52:117-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.semcancer.2017.12.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29229461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000446285900013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictive+markers+of+anti-VEGF+and+emerging+role+of+angiogenesis+inhibitors+as+immunotherapeutics.&amp;publication_year=2018&amp;journal=Semin+Cancer+Biol&amp;pages=117-124&amp;doi=10.1016%2Fj.semcancer.2017.12.002&amp;pmid=29229461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. <em>Cancer J</em> 2018;24:193-204.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/PPO.0000000000000327" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30119083/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452086500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Combinations+of+bevacizumab+with+cancer+immunotherapy.&amp;publication_year=2018&amp;journal=Cancer+J&amp;pages=193-204&amp;doi=10.1097%2FPPO.0000000000000327&amp;pmid=30119083" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with hepatocellular carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with advanced liver cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <em>Nature</em> 2014;515:563-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25428504/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346247600053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients.&amp;publication_year=2014&amp;journal=Nature&amp;pages=563-567&amp;doi=10.1038%2Fnature14011&amp;pmid=25428504" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. <em>Biochem Biophys Res Commun</em> 2005;333:328-335.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.bbrc.2005.05.132" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15961063/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230418700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bevacizumab+%28Avastin%29%2C+a+humanized+anti-VEGF+monoclonal+antibody+for+cancer+therapy.&amp;publication_year=2005&amp;journal=Biochem+Biophys+Res+Commun&amp;pages=328-335&amp;doi=10.1016%2Fj.bbrc.2005.05.132&amp;pmid=15961063" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. <em>Liver Int</em> 2009;29:284-290.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1478-3231.2008.01762.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18482274/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262284100026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+vascular+endothelial+growth+factor+with+the+monoclonal+antibody+bevacizumab+inhibits+human+hepatocellular+carcinoma+cells+growing+in+an+orthotopic+mouse+model.&amp;publication_year=2009&amp;journal=Liver+Int&amp;pages=284-290&amp;doi=10.1111%2Fj.1478-3231.2008.01762.x&amp;pmid=18482274" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. <em>J Clin Oncol</em> 2008;26:2992-2998.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2007.15.9947" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18565886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000256879700014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+trial+evaluating+the+clinical+and+biologic+effects+of+bevacizumab+in+unresectable+hepatocellular+carcinoma.&amp;publication_year=2008&amp;journal=J+Clin+Oncol&amp;pages=2992-2998&amp;doi=10.1200%2FJCO.2007.15.9947&amp;pmid=18565886" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with advanced liver cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] bevacizumab for hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. <em>Oncologist</em> 2012;17:1063-1072.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2011-0465" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22707516/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308126100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+biomarkers+of+single-agent+bevacizumab+therapy+in+patients+with+advanced+hepatocellular+carcinoma.&amp;publication_year=2012&amp;journal=Oncologist&amp;pages=1063-1072&amp;doi=10.1634%2Ftheoncologist.2011-0465&amp;pmid=22707516" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with advanced liver cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] bevacizumab for hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. <em>Expert Rev Anticancer Ther</em> 2009;9:503-509.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1586/era.09.6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19374603/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000265898300016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+angiogenesis+in+hepatocellular+carcinoma%3A+focus+on+VEGF+and+bevacizumab.&amp;publication_year=2009&amp;journal=Expert+Rev+Anticancer+Ther&amp;pages=503-509&amp;doi=10.1586%2Fera.09.6&amp;pmid=19374603" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Lee MS, Ryoo B-Y, Hsu C-H, et al. Randomised efficacy and safety results for atezolizumab (ATEZO) + bevacizumab (BEV) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). <em>Ann Oncol</em> 2019;30:Suppl 5:v875-v875. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.030" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30993330/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479284000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomised+efficacy+and+safety+results+for+atezolizumab+%28ATEZO%29+%2B+bevacizumab+%28BEV%29+in+patients+%28pts%29+with+previously+untreated%2C+unresectable+hepatocellular+carcinoma+%28HCC%29.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=v875-v875&amp;doi=10.1093%2Fannonc%2Fmdz394.030&amp;pmid=30993330" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] progression-free survival of 7 months. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] signaling in unresectable liver cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than with monotherapy with atezolizumab, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in the case of hepatocellular carcinoma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. <em>Hepatology</em> 2018;68:723-750.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.29913" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29624699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000441244400029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis%2C+staging%2C+and+management+of+hepatocellular+carcinoma%3A+2018+practice+guidance+by+the+American+Association+for+the+Study+of+Liver+Diseases.&amp;publication_year=2018&amp;journal=Hepatology&amp;pages=723-750&amp;doi=10.1002%2Fhep.29913&amp;pmid=29624699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. <em>Semin Liver Dis</em> 2010;30:52-60.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0030-1247132" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20175033/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000274665100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Modified+RECIST+%28mRECIST%29+assessment+for+hepatocellular+carcinoma.&amp;publication_year=2010&amp;journal=Semin+Liver+Dis&amp;pages=52-60&amp;doi=10.1055%2Fs-0030-1247132&amp;pmid=20175033" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. <em>Stat Med</em> 2009;28:586-604.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.3495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19051220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263005700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+graphical+approach+to+sequentially+rejective+multiple+test+procedures.&amp;publication_year=2009&amp;journal=Stat+Med&amp;pages=586-604&amp;doi=10.1002%2Fsim.3495&amp;pmid=19051220" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. <em>Hepatology</em> 2016;64:2038-2046.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.28710" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27359084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393900200059" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Programmed+death+ligand+1+expression+in+hepatocellular+carcinoma%3A+relationship+with+clinical+and+pathological+features.&amp;publication_year=2016&amp;journal=Hepatology&amp;pages=2038-2046&amp;doi=10.1002%2Fhep.28710&amp;pmid=27359084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <em>Lancet</em> 2019;393:2404-2415.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)30723-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31079938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471758200038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+plus+bevacizumab+versus+sunitinib+in+patients+with+previously+untreated+metastatic+renal+cell+carcinoma+%28IMmotion151%29%3A+a+multicentre%2C+open-label%2C+phase+3%2C+randomised+controlled+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2404-2415&amp;doi=10.1016%2FS0140-6736%2819%2930723-8&amp;pmid=31079938" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 13, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2004851" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Atezolizumab plus Bevacizumab â A Landmark in Liver Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.K. Kelley</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 12, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2021840" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Atezolizumab and Bevacizumab in Hepatocellular Carcinoma</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Rockport, Maine</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885458/neurologist-rockport-maine/?query=fjwp&amp;rid=1000">Neurologist - Rockport, Maine</a></div></div><div class="nejm-widget_item"><div><span> Amityville, New York</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/498223/inpatient-child-and-adolescent-psychiatrist-attending-south-oaks-hospital-amityville-ny/?query=fjwp&amp;rid=3059">INPATIENT CHILD AND ADOLESCENT PSYCHIATRIST ATTENDING - South Oaks Hospital, Amityville, NY</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/824124/seeking-various-dermatologists-across-northwell-health/?query=fjwp&amp;rid=3059">Seeking Various Dermatologists Across Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Mount Vernon, Illinois</span></div><div><span>Pulmonary / Critical Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882837/pulmonary-critical-care-physician/?query=fjwf&amp;rid=196467">Pulmonary Critical Care Physician</a></div></div><div class="nejm-widget_item"><div><span> San Marcos, Texas</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890300/ob-gyn-400000-00/?query=fjwf&amp;rid=346908">OB/GYN - $400000.00</a></div></div><div class="nejm-widget_item"><div><span> Oklahoma</span></div><div><span>Nephrology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886909/outstanding-opportunity-in-oklahoma-for-2026-supports-j-1-visa/?query=fjwf&amp;rid=316354">Outstanding Opportunity in Oklahoma for 2026 - Supports J-1 Visa</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1915745&amp;pubId=41288682&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d62b01425af1d2-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d62b01425af1d2-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d62b01425af1d2-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$400775918$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$400775918$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$400775918$--></div></div><div class="mlt-body"><!--?lit$400775918$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-ai" href="https://ai.nejm.org/browse/nejm-article-type/case-study?query=recirc_Semantic" target="_self"><!--?lit$400775918$-->Case Study</a> <span class="mlt-article-site-label"><!--?lit$400775918$-->NEJM AI</span> <span class="mlt-article-pubdate"><!--?lit$400775918$-->May 23, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://ai.nejm.org/doi/full/10.1056/AIcs2300235?query=recirc_Semantic" target="_self">GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines</a></div><div class="mlt-article-authors"><!--?lit$400775918$-->D. Ferber and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-implications-of-basic-research" target="_self"><!--?lit$400775918$-->Clinical Implications of Basic Research</a> <span class="mlt-article-site-label"><!--?lit$400775918$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$400775918$-->Jul 15, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcibr2106594?query=recirc_Semantic" target="_self">Hepatocellular Carcinoma â Origins and Outcomes</a></div><div class="mlt-article-authors"><!--?lit$400775918$-->R.K. Kelley and T.F. Greten</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$400775918$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$400775918$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$400775918$-->Jun 06, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070?query=recirc_Semantic" target="_self">Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$400775918$-->G.K. Abou-Alfa and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$400775918$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$400775918$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$400775918$-->May 04, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214963?query=recirc_Semantic" target="_self">TrifluridineâTipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer</a></div><div class="mlt-article-authors"><!--?lit$400775918$-->G.W. Prager and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$400775918$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$400775918$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$400775918$-->Sep 07, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=recirc_Semantic" target="_self">Atezolizumab for Advanced Alveolar Soft Part Sarcoma</a></div><div class="mlt-article-authors"><!--?lit$400775918$-->A.P. Chen and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1915745?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1915745" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1915745.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1915745"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1915928" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1915254" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f1.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/3eb2d908-01f0-4fc5-9e75-c18c7ab8aa6d/assets/images/large/nejmoa1915745_f1.jpg" height="2370" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">KaplanâMeier Analysis of Overall and Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival (Panel A) and progression-free survival (Panel B), as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1, for patients in the intention-to-treat population. Stratified hazard ratios for progression or death are reported, along with P values. The two-sided P-value boundary calculated on the basis of 161 deaths is 0.0033. Randomization was performed through an interactive voice-response or Web-response system, and factors included in the stratified P value and Cox model were geographic region (Asia [excluding Japan] vs. the rest of the world), alpha-fetoprotein level at baseline (&lt;400 ng per milliliter vs. â¥400 ng per milliliter), and macrovascular invasion, extrahepatic spread, or both (yes vs. no). Tick marks indicate censored data. CI denotes confidence interval, and NE could not be evaluated.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915745_f2.jpg"><img src="/cms/10.1056/NEJMoa1915745/asset/b59fbc43-f19b-4c1c-973c-cd57aa78c40e/assets/images/large/nejmoa1915745_f2.jpg" height="1331" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">KaplanâMeier Analysis of Time to Deterioration of Quality of Life.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of the time to deterioration in quality of life in the intention-to-treat population. Tick marks indicate censored data.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Patient Characteristics at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Secondary Efficacy Outcomes.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events from Any Cause.</div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t4" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 4</div><div class="fv__item__description"><figcaption>Adverse Events with an Incidence of More Than 10% in Either Group.</figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/20" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 20</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 14, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1915928" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.W. Armstrong and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 14, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1915254" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.R. Cohen and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 14, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1913808" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.M. Samama and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1915745%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1915745&amp;pubId=41288682&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1915745%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1915745&amp;pubId=41288682&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id045091342408206314" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d62b01425af1d2-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d62b01425af1d2-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d62b01425af1d2-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d62b01425af1d2-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d62b01425af1d2-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d62b01425af1d2-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d62b01425af1d2-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d62b01425af1d2-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d62b01425af1d2-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d62b01425af1d2-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d62b013c19f1d2',t:'MTc0OTUzMDE4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d62b013c19f1d2&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><kgo-vcwxymkrdtwm></kgo-vcwxymkrdtwm><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1915745?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-transactionid="h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" id="captureIFrame_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" target="captureIFrame_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="capture_screen"><input id="capture_signIn_js_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="js_version"><input id="capture_signIn_transactionId_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" type="hidden" class="capture_transactionId_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="capture_transactionId"><input id="capture_signIn_form_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="form"><input id="capture_signIn_flow_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="flow"><input id="capture_signIn_client_id_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="client_id"><input id="capture_signIn_redirect_uri_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="redirect_uri"><input id="capture_signIn_response_type_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="response_type"><input id="capture_signIn_flow_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="flow_version"><input id="capture_signIn_settings_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="settings_version"><input id="capture_signIn_locale_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="locale"><input id="capture_signIn_recaptcha_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_h3djrzdiek0c1gmyb8scmk7u7ljq4qqttftifdv9" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>